HK1189885B - 1',3'-disubstituted-4-pheny-3,4,5,6-tetrahydro-2h,1'h-[1,4'] bipyridinyl-2'-ones - Google Patents

Description

1 ', 3 ' -disubstituted-4-phenyl-3, 4,5, 6-tetrahydro-2H, 1 ' H- [1,4 ' ] bipyridinyl-2 ' -ones

The application is a divisional application of an invention patent application with the application date of 2008, 9 and 12, and the application number of 200880107135.0, and the invention name of the invention is ' 1 ', 3 ' -disubstituted-4-phenyl-3, 4,5, 6-tetrahydro-2H, 1 ' H- [1,4 ' ] bipyridinyl-2 ' -one '.

Technical Field

The present invention relates to novel pyridinone (pyridone) derivatives which are positive allosteric modulators of the metabotropic glutamate (metabotropic glutamate) receptor subtype 2 ("mGluR 2"), and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which mGluR2 is involved.

Background

Glutamate is the major amino acid neurotransmitter in the mammalian central nervous system. Glutamate plays a major role in a variety of physiological functions, such as learning and memory, but also in the development of sensory perception, synaptic plasticity, motor control, respiration, and regulation of cardiovascular function. Furthermore, glutamate is the focus of several different neurological and psychiatric diseases, where there is an imbalance in glutamatergic neurotransmission (glutamatergic neurotransmission).

Glutamate mediates synaptic neurotransmission by activating the ionized glutamate receptor channel (iGluR) and the NMDA, AMPA and kainate receptors that cause rapid excitatory transmission.

In addition, glutamate activates metabotropic glutamate receptors (mGluR), which have more modulatory effects that contribute to the fine-tuning of synaptic efficacy.

Glutamate activates mglurs by binding to the larger extracellular amino-terminal domain of the receptor, referred to herein as the orthosteric binding site. This binding causes a conformational change in the receptor which leads to the activation of the G-protein and the intracellular signaling pathway (intracellular signaling pathway).

The mGluR2 subtype is negatively coupled to adenylate cyclase through activation of G α i-protein, and activation of G α i-protein leads to inhibition of glutamate release in the synapse. In the Central Nervous System (CNS), mGluR2 receptors are abundant mainly in the entire cortex, thalamic regions, accessory olfactory bulb (olfactory bulb), hippocampus, amygdala, caudate-puten, and nucleus accumbens (nucleus accumbens).

Activated mGluR2 has been shown in clinical trials to be effective in the treatment of anxiety disorders. In addition, activated mGluR2 has been shown to be effective in a variety of animal models, and therefore represents a potentially novel therapeutic approach for the treatment of schizophrenia, epilepsy, addiction/drug dependence, parkinson's disease, pain, sleep disorders, and Huntington's disease.

To date, the majority of available pharmaceutical tools targeting mglurs are forward ligands (orthosteric ligands), which activate several members of the family, as they are structural analogues of glutamate.

One new approach for developing selective compounds that act at mglurs is to identify compounds that act through allosteric mechanisms, where the receptor is modulated by binding to a site distinct from the highly conserved orthosteric binding site.

Recently, positive allosteric modulators of mglurs have emerged as novel pharmaceutical entities offering this attractive alternative (alternative). As mGluR2 positive allosteric modulators, a variety of compounds have been described. WO2004/092135(NPS & Astra Zeneca), WO2004/018386, WO2006/014918 and WO2006/015158(Merck), WO2001/56990(Eli Lilly) and WO2006/030032 (Addex & Janssen Pharmaceutica) describe benzenesulfonamides, acetophenones (acetophenones), indanones, pyridylmethyl sulfonamides and pyridone derivatives, respectively, as mGluR2 positive allosteric modulators. None of the specifically disclosed compounds are structurally related to the compounds of the present invention.

It was confirmed that such compounds do not activate the receptor by themselves. Rather, they are able to maximize the response of the receptor to a concentration of glutamate that itself causes the least response. Mutational analysis has clearly demonstrated that binding of mGluR2 positive allosteric modulators does not occur at the positive allosteric site, but rather at an allosteric site located within seven transmembrane regions of the receptor.

Animal data suggest that positive allosteric modulators of mGluR2 have effects in anxiety and psychosis models similar to those obtained with positive agonists (orthosteric agonists). Allosteric modulators of mGluR2 were shown to play a role in fear-enhanced startle, as well as in stress-induced hyperthermia models of anxiety. Furthermore, such compounds have been shown to play a role in the restoration of ketamine (ketamine) or amphetamine-induced accelerated locomotion (hypercocomposition), and in the restoration of the disruption of prepulse inhibition in the amphetamine-induced acoustic startle effect model of schizophrenia (J.Pharmacol. exp. Ther.2006,318,173-185; Psychopharmacology2005,179, 271-283).

Recent animal studies have further revealed a hallucinogenic drug model of the selective positive allosteric modulator of metabotropic glutamate receptor subtype 2, Biphenyl Indanone (BINA), inhibiting psychosis, supporting a strategy to target mGluR2 receptors for the treatment of glutamate dysfunction in schizophrenia (mol. pharmacol.2007,72, 477-.

Positive allosteric modulators are capable of potentiating glutamate responses, but they have also been shown to potentiate responses to positive mGluR2 agonists such as LY379268 or DCG-IV. These data also provide evidence demonstrating a further novel therapeutic approach to treat the above-mentioned neurological and psychiatric disorders involving mGluR2, using a combination of a positive allosteric modulator of mGluR2 and a positive agonist of mGluR 2.

Disclosure of Invention

The present invention relates to compounds having metabotropic glutamate receptor 2 modulator activity, which compounds have the formula (I)

And stereochemically isomeric forms thereof, wherein

R¹Is C_1-6An alkyl group; or with C_3-7Cycloalkyl, phenyl, or C substituted by halogen-, trifluoromethyl-or trifluoromethoxy-substituted phenyl_1-3An alkyl group;

R²is halogen, trifluoromethyl, C_1-3Alkyl or cyclopropyl;

R³is hydrogen, fluorine, hydroxy C_1-3Alkyl, hydroxy C_1-3Alkoxy, fluoro C_1-3Alkyl, fluoro C_1-3Alkoxy or cyano; and

ar is unsubstituted phenyl; or with n radicals R⁴Substituted phenyl, wherein n is 1,2 or 3;

R⁴selected from hydrogen, halogen, C_1-3Alkyl, hydroxy C_1-3Alkyl, polyhalo C_1-3Alkyl, cyano, hydroxy, amino, carboxyl, C_1-3Alkoxy radical C_1-3Alkyl radical, C_1-3Alkoxy, polyhalo C_1-3Alkoxy radical, C_1-3Alkylcarbonyl, mono and di (C)_1-3Alkyl) amino, and morpholinyl; or

Two adjacent (vicinal) R⁴The groups being linked together to form a divalent radical of the formula

–N=CH-NH-(a)，

-CH = CH-NH- (b), or

-O-CH₂-CH₂-NH- (c); or

Ortho R³And R⁴The groups being linked together to form a divalent radical of the formula

-CH₂-O- (d), or

-O-CH₂-(e)；

And pharmaceutically acceptable salts and solvates thereof.

In one embodiment, the present invention relates to a compound of formula (I) or a stereochemically isomeric form thereof, wherein

R¹Is C_1-6An alkyl group; or with C_3-7Cycloalkyl, phenyl, or with halogen, trifluoromethyl or trifluoroMethoxy substituted phenyl substituted C_1-3An alkyl group;

R²is halogen, trifluoromethyl, C_1-3Alkyl or cyclopropyl;

R³is hydrogen, fluorine, hydroxy C_1-3Alkyl, hydroxy C_1-3Alkoxy, fluoro C_1-3Alkyl, fluoro C_1-3Alkoxy or cyano; and

ar is unsubstituted phenyl, or with n radicals R⁴Substituted phenyl, wherein n is 1,2 or 3;

R⁴selected from hydrogen, halogen; c_1-3An alkyl group; hydroxy radical C_1-3Alkyl, polyhalo C_1-3An alkyl group; a cyano group; a hydroxyl group; an amino group; a carboxyl group; c_1-3Alkoxy radical C_1-3An alkyl group; c_1-3An alkoxy group; polyhalo C_1-3An alkoxy group; c_1-3An alkylcarbonyl group; mono (C)_1-3Alkyl) amino and di (C)_1-3Alkyl) amino, morpholinyl; or

Two adjacent R4 groups are linked together to form a divalent group of the formula

–N=CH-NH-(a)，

-CH = CH-NH- (b), or

-O-CH₂-CH₂-NH- (c); and pharmaceutically acceptable salts and solvates thereof.

In one embodiment, the present invention relates to a compound according to formula (I) or a stereochemically isomeric form thereof, wherein

R¹Is 1-butyl, 2-methyl-1-propyl, 3-methyl-1-butyl, (cyclopropyl) methyl or 2- (cyclopropyl) -1-ethyl;

R²is chloro, bromo, cyclopropyl or trifluoromethyl;

R³is hydrogen, fluoro or cyano; and

ar is unsubstituted phenyl; or with halogen, trifluoromethyl, morpholinyl or hydroxy C_1-3Alkyl-substituted phenyl;

or a pharmaceutically acceptable salt or solvate thereof.

In one embodiment, the present invention relates to a compound according to formula (I) or a stereochemically isomeric form thereof, wherein

R¹Is 1-butyl, 3-methyl-1-butyl, (cyclopropyl) methyl or 2- (cyclopropyl) -1-ethyl;

R²is chlorine;

R³is hydrogen or fluorine; and

ar is unsubstituted phenyl; or with hydroxy groups C_1-3Alkyl-substituted phenyl;

or a pharmaceutically acceptable salt or solvate thereof.

In one embodiment, the invention relates to compounds

3 ' -chloro-1 ' -cyclopropylmethyl-4-phenyl-3, 4,5, 6-tetrahydro-2H, 1 ' H- [1,4 ' ] bipyridinyl-2 ' -one (E1) or

1 ' -butyl-3 ' -chloro-4-phenyl-3, 4,5, 6-tetrahydro-2H, 1 ' H- [1,4 ' ] bipyridinyl-2 ' -one (E2).

Symbol C as a group or part of a group_1-3Alkyl defines saturated, straight-chain or branched hydrocarbon radicals having from 1 to 3 carbon atoms, such as methyl, ethyl, 1-propyl and 1-methylethyl; for example, hydroxy group C_1-3Alkyl defines, for example, hydroxymethyl, 2-hydroxyethyl, 3-hydroxypropyl and 1-hydroxy-1-methylethyl.

Symbol C as a group or part of a group_1-6Alkyl defines a saturated, straight-chain or branched hydrocarbon radical having from 1 to 6 carbon atoms, such as methyl, ethyl, 1-propyl, 1-methylethyl, 1-butyl, 2-methyl-1-propyl, 3-methyl-1-butyl1-pentyl, 1-hexyl and the like.

Symbol C_3-7Cycloalkyl defines saturated cyclic hydrocarbon radicals having from 3 to 7 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.

The symbols halo (halo) or halogen as a group or part of a group are generic for fluoro (fluoro), chloro (chloro), bromo (bromo), iodo (iodo).

For therapeutic use, salts of the compounds of formula (I) are those in which the counter ion (counterion) is pharmaceutically acceptable. However, salts of non-pharmaceutical (non-pharmaceutically acceptable) acids and bases may also be used, for example, in the preparation or purification of a pharmaceutical compound. All salts, whether pharmaceutically acceptable or not, are included within the scope of the invention.

Pharmaceutically acceptable salts are defined to include the therapeutically active non-toxic acid addition salt forms which the compounds according to formula (I) are able to form. The salts may be obtained by treating the basic form of the compound according to formula (I) with a suitable acid, for example an inorganic acid, such as a hydrohalic acid, especially hydrochloric, hydrobromic, sulfuric, nitric and phosphoric acids; organic acids, such as acetic acid, glycolic acid, propionic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, maleic acid, fumaric acid, malic acid, tartaric acid, citric acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, cyclamic acid, salicylic acid, p-aminosalicylic acid and pamoic acid (pamoic acid).

Conversely, the salt form may be converted to the free base form by treatment with a suitable base.

The compounds according to formula (I) containing an acidic proton can also be converted into their therapeutically active non-toxic base salt forms by treatment with suitable organic and inorganic bases. Suitable base salt forms include, for example, the ammonium salts, the alkali and alkaline earth metal salts, especially the lithium, sodium, potassium, magnesium and calcium salts, salts with organic bases, for example benzathine, N-methyl-D-glucamine, hydroxylamine salts (hybramine salt), and salts with amino acids, for example arginine and lysine.

Conversely, the salt form may be converted to the free acid form by treatment with an appropriate acid.

The term solvate includes the solvent addition forms (solvent addition forms) which the compound of formula (I) is capable of forming, as well as salts thereof. Examples of such solvent addition forms are, for example, hydrates, alcoholates and the like.

The term "stereochemically isomeric forms" as used hereinbefore defines all the possible isomeric forms which the compounds of formula (I) may possess. Unless otherwise mentioned or indicated, the chemical name (nomenclature) of a compound denotes the mixture of all possible stereochemically isomeric forms, said mixtures comprising all diastereomers and enantiomers of the basic molecular structure. The present invention also includes each individual isomeric form of the compounds of formula (I) and their salts and solvates, substantially free, i.e. with less than 10%, preferably less than 5%, especially less than 2%, and most preferably less than 1% of the other isomers. Thus, for example, when a compound of formula (I) is designated as (R), this means that the compound is substantially free of the (S) isomer. The Stereogenic centers may have either the R-or S-configuration; the substituents on the divalent cyclic (partially) saturated groups may have either the cis or trans configuration.

According to the CAS nomenclature rules, when two stereogenic centers of known absolute configuration are present in a compound, the R or S descriptor is assigned (based on Cahn-Ingold-Prelog order rule) to the lowest numbered chiral center, the reference center. The configuration of the center of the second stereogene is shown using the relevant descriptors [ R, R ] or [ R, S ], where R is always designated as the reference center and [ R, R ] denote centers with the same chirality and [ R, S ] denote centers of different chirality. For example, if the lowest numbered chiral center in a compound has the S configuration and the second center is R, the stereodescriptor will be designated S- [ R, S ]. If "α" and "β" are used, the position of the highest priority substituent on the asymmetric carbon atom in the ring system with the least number of rings is always arbitrarily at the "α" position of the plane (mean plane) defined by the ring system. The position of the highest priority substituent on another asymmetric carbon atom in the ring system (hydrogen atom in the compound according to formula (I)) relative to the position of the highest priority substituent on the reference atom is designated "a" if it is on the same side of the mean plane defined by the ring system, or "β" if it is on the other side of the mean plane defined by the ring system.

In the framework of this application, an element, especially when mentioned in relation to a compound according to formula (I), includes all isotopes and isotopic mixtures of this element, naturally occurring or synthetically produced, in natural abundance or in isotopically enriched form. The radiolabeled compound of formula (I) may include a compound selected from³H、¹¹C、¹⁸F、¹²²I、¹²³I、¹²⁵I、 ¹³¹I、⁷⁵Br、⁷⁶Br、⁷⁷Br and⁸²radioisotopes of the group of Br. Preferably, the radioisotope is selected from³H、¹¹C and¹⁸and F.

Preparation of

The compounds according to the invention can generally be prepared by a series of steps, each of which is known to the skilled person. In particular, the compound can be prepared according to the following synthetic method.

The compounds of formula (I) can be synthesized as racemic mixtures of enantiomers, which can be separated from each other according to resolution procedures known in the art. The racemic compounds of formula (I) can be converted into the corresponding diastereomeric salt forms by reaction with a suitable chiral acid. The diastereomeric salt forms are subsequently separated, for example by selective or fractional crystallization, and the enantiomers are liberated therefrom by means of a base. An alternative way of separating the enantiomeric forms of the compounds of formula (I) involves liquid chromatography using a chiral stationary phase. The pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occurs stereospecifically.

A. Preparation of the Final Compounds

Experimental procedure (flow) 1

A compound according to formula (I) (in R)²In the case of halogen) can be prepared by reacting the intermediate of formula (II) with an N-halosuccinimide reagent, such as N-chlorosuccinimide, N-bromosuccinimide, or N-iodosuccinimide, according to reaction scheme (1). The reaction is carried out in a suitable reaction-inert solvent and an aprotic solvent, such as, for example, dichloromethane or 1, 2-dichloroethane, and the reaction mixture is stirred at a suitable temperature, usually at room temperature, for the time required to achieve completion of the reaction, usually 1 hour. In reaction scheme (1), R²Is halogen and all other variables are as defined in formula (I).

Reaction scheme 1

Experimental procedure 2

Alternatively, compounds according to formula (I) may be prepared by reacting an intermediate of formula (III) with an intermediate of formula (IV), which may be commercially available or may be synthesized by procedures well known to any person skilled in the art, according to reaction scheme (2). The reaction is carried out in a suitable reaction-inert solvent, for example tolueneSuitable bases (e.g. sodium tert-butoxide), metal-based catalysts, in particular palladium catalysts, such as palladium (II) acetate, and suitable ligands, for example [1, 1' -binaphthalene]-2, 2' -bis [ diphenylphosphine)](BINAP) is carried out in the presence of heat to complete the reaction for a suitable time, for example 16 hours at 100 ℃ in a sealed tube. In reaction scheme (2), Z^aAre suitable groups for Pd-mediated coupling of amines, such as, for example, halogen or triflate. All other variables are as defined in formula (I).

Reaction scheme 2

Such intermediates of formula (II) and formula (III) can be prepared according to reaction schemes (3) to (11) (see below). The conversion of the different functional groups present in the final compound into other functional groups according to formula (I) can be performed by synthetic methods well known to the person skilled in the art.

Furthermore, compounds according to formula (I) may be prepared by the skilled person using procedures known in the art by further modifying compounds of formula (I):

-alkylating compounds of formula (I) containing one or more hydroxyl substituents in their structure with a suitable alkylating agent such as fluoroethyl p-toluenesulfonate in a suitable reaction inert solvent (e.g. 1, 2-dimethoxyethane or dimethylformamide) under thermal conditions using a suitable base such as sodium hydride.

-fluorinating compounds of formula (I) containing one or more hydroxyl substituents in their structure with a suitable fluorinating agent, such as, for example, (diethylamino) sulfur trifluoride. The reaction may be carried out in a suitable reaction inert solvent (e.g. dichloromethane) at moderately low temperatures, such as for example at temperatures in the range of-78 ℃ to 30 ℃ for e.g. 0.5 to 12 hours.

Reacting compounds of formula (I) containing one or more hydroxyl substituents in their structure with alcohol derivatives under thermal conditions by using suitable coupling systems, such as, for example, di-tert-butyl azodicarboxylate/triphenylphosphine.

B. Preparation of intermediates

Experimental procedure 3

Intermediates of formula (II) can be prepared by reacting an intermediate of formula (V) with an intermediate of formula (IV) according to reaction scheme (3). The reaction is carried out in a suitable reaction inert solvent (e.g., toluene), in the presence of a suitable base (e.g., sodium tert-butoxide), a metal-based catalyst, specifically a palladium catalyst such as palladium (II) acetate, and a suitable ligand such as [1,1 '-binaphthalene ] -2, 2' -bis [ diphenylphosphine ] (BINAP), and heated to complete the reaction for a suitable time, for example, up to 16 hours at 100 ℃ in a sealed tube. In reaction scheme (3), all variables are as defined in formula (I).

Reaction scheme 3

Experimental procedure 4

Can be prepared by reacting an intermediate of formula (VI) wherein Y is H or R²(as defined in formula I) with a suitable halogenating agent, for example phosphorus oxybromide, to prepare intermediates of formulae (III-a) and (III-b). The reaction may be carried out in a suitable reaction inert solvent, such as DMF, at moderately elevated temperatures, such as, for example, 110 ℃, for a suitable time, such as, for example, 1 hour, to complete the reaction. In reaction scheme (4), the variable R¹As defined in formula (I).

Reaction scheme 4

Experimental procedure 5

The intermediate of formula (III-c) can be prepared by reacting the intermediate of formula (VI-a) with triflic anhydride (triflic anhydride). The reaction may be carried out in a suitable reaction-inert solvent, such as dichloromethane, in the presence of a base, such as pyridine, at low temperatures, such as, for example, -78 ℃. In reaction scheme (5), all variables are as defined in formula (I).

Reaction scheme 5

Experimental procedure 6

Intermediates of formula (VI) may be prepared by hydrogenolysis of intermediates of formula (VII-a, VII-b or VII-c) in the presence of a catalyst (e.g. 10% palladium on activated carbon) in a suitable reaction inert solvent such as, for example, ethanol, typically at room temperature and 1 atmosphere of hydrogen for 2 hours, to ensure time for the reaction to complete. In reaction scheme (6), the variable R¹As defined in formula (I).

Reaction scheme 6

Experimental procedure 7

Alternatively, the intermediate of formula (VI) (wherein Y = halogen) may beTo be prepared by reacting the intermediate of formula (VII-d) in a mixture of acetic acid and hydrobromic acid and heating the mixture to completion for the required time, typically 30 minutes at 130 ℃ under microwave irradiation. In reaction scheme (7), the variable R¹As defined in formula (I).

Reaction scheme 7

Experimental procedure 8

Intermediates of formula (VII-a) can be prepared by procedures known in the art by reacting a commercially available 4-benzyloxy-1H-pyridin-2-one with a commercially available alkylating agent of formula (VIII), wherein Z is^bAre suitable leaving groups, wherein the reaction utilizes a base, such as, for example, K₂CO₃And optionally an iodide salt, such as, for example KI, in an inert solvent, such as, for example, acetonitrile or DMF, at moderately elevated temperature, such as, for example, 80-120 ℃, for a suitable time for the reaction to complete, for example 16 hours. In reaction scheme (8), the variable R¹As defined in formula (I), and Z^bAre suitable leaving groups such as, for example, halogen.

Reaction scheme 8

Experimental procedure 9

Intermediates of formula (VII-b) may be prepared by reacting an intermediate of formula (VII-e) wherein Y is iodine with commercially available methyl 2, 2-difluoro-2- (fluorosulfonyl) acetate in a suitable reaction-inert solvent (e.g., DMF) in the presence of a suitable copper salt such as copper (I) iodideShould be prepared by heating to complete the reaction for a suitable time, for example 5 hours at 100 ℃. In reaction scheme (9), the variable R¹As defined in formula (I).

Reaction scheme 9

Experimental procedure 10

Intermediates of formula (VII-d) may be prepared by reacting an intermediate of formula (VII-a) with a commercially available N-halosuccinimide, such as N-chlorosuccinimide (NCS), N-bromosuccinimide (NBS) or N-iodosuccinimide (NIS), in a suitable reaction-inert solvent (e.g., DMF, dichloromethane or acetic acid), typically at room temperature for 1 to 24 hours. In reaction scheme (10), the variable R¹As defined in formula (I).

Reaction scheme 10

Experimental procedure 11

The intermediate of formula (VII-C) may be prepared by reacting an intermediate of formula (VII-d) with C_1-3Alkyl or cyclopropylboronic acid derivatives, such as cyclopropylboronic acid or methylboronic acid, in a suitable reaction inert solvent (e.g., 1, 4-dioxane) in a suitable palladium catalyst complex (e.g., [1, 1' -bis (diphenylphosphino) ferrocene]Palladium dichloride-DCM complex) and in the presence of a suitable base (e.g. sodium bicarbonate), for a suitable time to complete the reaction, for example 20 minutes at 175 ℃. In reaction scheme (11), the variable R¹As defined in formula (I).

Reaction scheme 11

Experimental procedure 12

Intermediates of formula (IV) can be prepared by deprotecting the piperidine nitrogen in intermediates of formula (IX) according to reaction scheme (12) using procedures known in the art, wherein L is a suitable protecting group for the nitrogen atom of the piperidine derivative, such as, for example, t-butyloxycarbonyl, ethoxycarbonyl, benzyloxycarbonyl, benzyl and methyl. In reaction scheme (12), all variables are as defined in formula (I).

Reaction scheme (12)

Experimental procedure 13

Intermediates of formula (IV-a) can be prepared by hydrogenation of intermediates of formula (X) according to reaction scheme (13) using procedures known in the art. In reaction scheme (13), Ar is as defined in formula (I).

Reaction scheme (13)

Experimental procedure 14

Intermediates of formula (IX-a) can be prepared by hydrogenation of intermediates of formula (XI) wherein L is a suitable protecting group for the nitrogen atom of the tetrahydropyridine derivative, such as, for example, t-butoxycarbonyl, ethoxycarbonyl, benzyloxycarbonyl, benzyl and methyl, following reaction scheme (14) using procedures known in the art. In reaction scheme (14), Ar is as defined in formula (I).

Reaction scheme (14)

Experimental procedure 15

Intermediates of formula (X) can be prepared by deprotecting the tetrahydropyridine nitrogen in intermediates of formula (XI) wherein L is a suitable protecting group for the nitrogen atom of the tetrahydropyridine derivative, such as, for example, t-butoxycarbonyl, ethoxycarbonyl, benzyloxycarbonyl, benzyl and methyl, following reaction scheme (15), using procedures known in the art. In reaction scheme (15), Ar is as defined in formula (I).

Reaction scheme (15)

Experimental procedure 16

Intermediates of formula (XI) are prepared by reacting an intermediate of formula (XII) with an intermediate of formula (XIII) according to reaction scheme (16). The reaction is carried out in a suitable reaction inert solvent (e.g., 1, 4-dioxane), or a mixture of inert solvents (e.g., 1, 4-dioxane/DMF), in a suitable base such as aqueous NaHCO₃Or Na₂CO₃Suitable catalysts, such as Pd complex catalysts (e.g., Pd (PPh)₃)₄) The reaction mixture is heated under thermal conditions, for example under microwave irradiation, at 150 ℃, for example for 10 minutes. In reaction scheme (16), all variables are as defined in formula (I); z^cIs suitable for Pd-mediated reaction with boronAcid or boron ester (boronic ester) coupling groups, such as, for example, halogen or trifluoromethanesulfonic acid; l is a suitable protecting group for the nitrogen atom of tetrahydropyridine derivatives, such as, for example, tert-butoxycarbonyl, ethoxycarbonyl, benzyloxycarbonyl, benzyl and methyl, and R₄And R₅Is hydrogen or C_1-4Alkyl groups, or may be linked together to form, for example, the formula-CH₂CH₂-、-CH₂CH₂CH₂-, or-C (CH)₃)₂C(CH₃)₂A divalent radical of (a).

Reaction scheme (16)

Experimental procedure 17

An intermediate of formula (IV) wherein R₃Represents fluorine or C substituted by fluorine_1-3Alkyl radical, said R₃from-L₁-F represents wherein L₁Is represented by C_1-3Alkyl or covalent bond, and said intermediate is represented by formula (IV-b), can be prepared by procedures known in the art by reacting an intermediate of formula (IX-b), wherein L is a suitable protecting group for the nitrogen atom of the piperidine group, e.g., t-butoxycarbonyl, ethoxycarbonyl, benzyloxycarbonyl, benzyl and methyl, with a suitable fluorinating agent, e.g., (diethylamino) sulfur trifluoride, according to step (a) of reaction scheme (17), to produce an intermediate of formula (IX-c). The reaction may be carried out in a suitable reaction-inert solvent (e.g., dichloromethane). The reaction may be carried out at moderately low temperatures, for example in the range of-78 ℃ to 30 ℃, for example 0.5 to 12 hours. The resulting intermediate of formula (IX-c) can then be converted to an intermediate of formula (IV-b) by deprotecting the piperidine nitrogen using procedures known in the art, such as those described in experimental procedure 15 above, according to step (b) of reaction scheme (17). In reaction scheme (17), Ar is as defined in formula (I).

Reaction scheme (17)

Experimental procedure 18

Intermediates of formula (IV) (wherein R₃Represents C substituted by fluorine_1-3Alkoxy radical, said C_1-3Alkoxy is represented by Q, and R is₃Represented by-Q-F and said intermediate represented by formula (IV-d) can be prepared by procedures known in the art by reacting a hydroxy-substituted intermediate of formula (IX-d), wherein L is a suitable protecting group for the nitrogen atom of the piperidine group, e.g., tert-butoxycarbonyl, ethoxycarbonyl, benzyloxycarbonyl, benzyl and methyl, with a suitable fluorinating agent such as (diethylamino) sulfur trifluoride, following step (a) of reaction scheme (18), to produce an intermediate of formula (IX-e). The reaction may be carried out in a suitable reaction inert solvent (e.g., dichloromethane) at moderately low temperatures, e.g., in the range of-78 ℃ to 30 ℃, e.g., for 0.5 to 12 hours. Intermediates of formula (IX-e) can then be converted to intermediates of formula (IV-d) by deprotecting the piperidine nitrogen using procedures known in the art, such as those described in Experimental procedure 17 above, according to step (b) of reaction scheme (18). In reaction scheme (18), Ar is as defined in formula (I).

Reaction scheme (18)

Experimental procedure 19

An intermediate of formula (IX-b) (wherein L1 represents CH)₂And the intermediate is represented by the formula (IX-f) can be produced by reacting a compound of the formula (XIV)Intermediates (wherein L is a suitable protecting group for the nitrogen atom of the piperidine group, e.g., t-butoxycarbonyl, ethoxycarbonyl, benzyloxycarbonyl, benzyl, and methyl) with a suitable reducing agent (e.g., lithium aluminum hydride) according to reaction scheme (19). The reaction may be carried out in a suitable solvent (e.g., tetrahydrofuran) at moderately low temperatures, e.g., -20 ℃. In reaction scheme (19), Ar is as defined in formula (I).

Reaction scheme (19)

Starting materials according to formulae (VIII), (IX-b), (IX-d), (XII), (XIII) and XIV are commercially available or can be prepared according to conventional reaction procedures generally known to the person skilled in the art.

Pharmacology of

The compounds provided in the present invention are positive allosteric modulators of metabotropic glutamate receptors, and in particular, they are positive allosteric modulators of mGluR 2. The compounds of the invention do not exhibit binding to the glutamate recognition site, the orthosteric ligand site, but rather exhibit binding to allosteric sites within the seven transmembrane regions of the receptor. The compounds of the invention increase mGluR2 responses in the presence of glutamate or mGluR2 agonists. The compounds provided in the present invention are expected to have an effect in mGluR2, increasing the response of such receptors, due to their ability to increase the response of such receptors to glutamate or mGluR2 agonists. The present invention therefore relates to a compound according to the present invention for use as a medicament and to the use of a compound according to the present invention or a pharmaceutical composition according to the present invention for the manufacture of a medicament for the treatment or prevention, especially the treatment, of a condition in a mammal, including a human, which treatment or prevention is influenced or facilitated by the neuromodulatory effect (neuromodulatory effect) of allosteric modulators of mGluR2, especially positive allosteric modulators thereof. The invention also relates to a compound according to the invention or a pharmaceutical composition according to the invention for use in the manufacture of a medicament for the treatment or prevention, especially treatment, of a condition in a mammal, including a human, which treatment and prevention is affected or facilitated by the neuromodulatory effect of allosteric modulators of mGluR2, especially positive allosteric modulators thereof. The invention also relates to a compound according to the invention or a pharmaceutical composition according to the invention for use in the treatment or prevention, especially the treatment, of a condition in a mammal, including a human, which treatment and prevention is influenced or facilitated by the neuromodulatory effect of allosteric modulators of mGluR2, especially positive allosteric modulators thereof.

Furthermore, the present invention also relates to the use of a compound according to the present invention or a pharmaceutical composition according to the present invention for the manufacture of a medicament for the treatment, prevention, alleviation, control or reduction of the risk of various neurological and psychiatric disorders associated with glutamate dysfunction, which treatment or prevention is affected or facilitated by the neuromodulatory effect of positive allosteric modulators of mGluR2, in a mammal, including a human.

Where the invention is said to relate to the use of a compound or composition according to the invention in the manufacture of a medicament, for example for the treatment of a mammal, it is to be understood that in certain jurisdictions such use is to be interpreted as, for example, a method of treating a mammal comprising administering to a mammal in need of such treatment an effective amount of a compound or composition according to the invention.

In particular, neurological and psychiatric disorders associated with glutamate dysfunction include one or more of the following conditions or diseases: acute neurological and psychiatric disorders such as, for example, cardiac bypass surgery and post-transplant brain defects, stroke, cerebral ischemia, spinal cord injury, head trauma, perinatal hypoxia, cardiac arrest, hypoglycemic neuronal injury, dementia (including AIDS-induced dementia), Alzheimer's disease, Huntington's chorea, amyotrophic lateral sclerosis, eye injury, retinopathy, cognitive disorders, idiopathic and drug-induced parkinsonism, muscle spasms and related disorders includingTremor, epilepsy, disorders associated with muscular spasticity (muscular spasticity) of twitching, migraine (periodic migraine), urinary incontinence, substance tolerance (substention tolerance), substance withdrawal (substention withdrawal) (including, for example, opiates, nicotine, smoking articles, alcohol, benzodiazepines, nicotine, alcohol, benzodiazepines, and the likeSubstances such as cocaine, sedatives, hypnotics, etc.), psychosis, schizophrenia, anxiety (including generalized anxiety disorder (generalized anxiety disorder), psychological imbalance disorder (systemic disorder) and obsessive-compulsive disorder (obsessive-compulsive disorder)), mood disorders (including depression, mania, bipolar disorders), trigeminal neuralgia, hearing loss, tinnitus, ocular macular degeneration, emesis, cerebral edema, pain (including acute and chronic states, severe pain, intractable pain, neuropathic pain, post-traumatic pain), tardive dyskinesia, sleep disorders (including narcolepsy), attention deficit/hyperactivity disorder (hyperkinesia disorder), and conduct disorder.

In particular, the condition or disease is a central nervous system disorder selected from the group consisting of anxiety disorders, psychotic disorders, personality disorders, substance-related disorders, eating disorders, mood disorders, migraine, epilepsy or convulsive disorders, childhood disorders, cognitive disorders, neurodegeneration, neurotoxicity and ischemia.

Preferably, the central nervous system disorder is an anxiety disorder selected from the group of agoraphobia (agoraphobia), Generalized Anxiety Disorder (GAD), obsessive-compulsive disorder (OCD), psychological imbalance disorder (systemic disorder), post-traumatic stress disorder (PTSD), social phobia, and other phobias.

Preferably, the central nervous system disorder is a psychotic disorder (psychotic disorder) selected from the group of schizophrenia, delusional disorder (delusional disorder), schizoaffective disorder (schizophrenia disorder), schizophreniform disorder (schizophreniform disorder) and substance-induced psychotic disorder.

Preferably, the central nervous system disorder is a personality disorder selected from the group of obsessive-compulsive personality disorder (obsessive-compulsive personality disorder) and schizophreniform, schizotypal disorder (schizotypal disorder).

Preferably, the central nervous system disorder is a substance-related disorder selected from the group of alcohol abuse, alcohol dependence, alcohol withdrawal (alcohol withdrawal), alcohol withdrawal delirium (alcohol withdrawal delirium), alcohol-induced psychotic disorder, amphetamine dependence, amphetamine withdrawal, cocaine dependence, cocaine withdrawal, nicotine dependence, nicotine withdrawal, opioid dependence and opioid withdrawal.

Preferably, the central nervous system disorder is an eating disorder selected from the group of anorexia nervosa and bulimia nervosa.

Preferably, the central nervous system disorder is a mood disorder selected from the group of bipolar disorders (type I and type II), cyclothymic disorder, depression, dysthymic disorder, major depressive disorder and substance-induced mood disorder.

Preferably, the central nervous system disorder is migraine.

Preferably, the central nervous system disorder is epilepsy or a convulsive disorder selected from the group of generalized nonconvulsive epilepsy, generalized convulsive epilepsy, petit mal status epilepticus, grand mal status epilepticus, partial epilepsy with or without impairment of consciousness (partial epilepsy), infantile spasms, partial status epilepticus and other forms of epilepsy.

Preferably, the central nervous system disorder is attention deficit/hyperactivity disorder.

Preferably, the central nervous system disorder is a cognitive disorder selected from the group of delirium, substance-induced persisting delirium, dementia due to HIV disease, dementia due to huntington's chorea, dementia due to parkinson's disease, dementia of the alzheimer's type, substance-induced persisting dementia and mild cognitive impairment.

Of the disorders mentioned above, the treatment of anxiety, schizophrenia, migraine, depression and epilepsy is of particular importance.

Currently, the Diagnostic & Statistical Manual of Mental Disorders fourth edition (DSM-IV) of the American psychiatric Association provides a Diagnostic tool for identifying the Disorders described herein. Those skilled in the art will recognize that there are alternative nomenclature, nosologies, and classification systems for neurological and psychiatric disorders described herein, and that they evolve with medical and scientific progress.

Because such positive allosteric modulators of mGluR2, including compounds of formula (I), can increase the response of mGluR2 to glutamate, it is advantageous that the methods of the present invention utilize endogenous glutamate (endogenous glutamate).

Because positive allosteric modulators of mGluR2, including compounds of formula (I), can increase the response of mGluR2 to agonists, it should be understood that the present invention extends to the treatment of neurological and psychiatric disorders associated with glutamate dysfunction by administering a therapeutically effective amount of a combination of a positive allosteric modulator of mGluR2, including compounds of formula (I), and an mGluR2 agonist.

The compounds of the present invention may be used in combination with one or more other drugs for the treatment, prevention, control, alleviation, or reduction of the risk of a disease or condition for which a compound of formula (I) or other drug may have utility, wherein the drugs in combination together are safer or more effective than either drug alone.

Pharmaceutical composition

The present invention also relates to a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and, as active ingredient, a therapeutically effective amount of a compound according to the invention, in particular a compound according to formula (I), a pharmaceutically acceptable salt thereof, a solvate thereof or a stereochemically isomeric form thereof.

For administration use, the compounds according to the invention, in particular the compounds according to formula (I), their pharmaceutically acceptable salts, solvates and stereochemically isomeric forms, or any subgroup or combination thereof, may be formulated into various pharmaceutical forms. As suitable compositions, all compositions usually used for systemic administration of drugs can be cited.

To prepare the pharmaceutical compositions of this invention, an effective amount of the particular compound, optionally in salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier or diluent, which carrier or diluent may take a wide variety of forms depending on the form of preparation desired for administration (preparation). These pharmaceutical compositions are desirably in a single dosage form particularly suitable for administration orally, rectally, transdermally, by parenteral injection or by inhalation. For example, in preparing the oral dosage form compositions, any of the usual pharmaceutical media (pharmacological media) may be employed, such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations (e.g., suspensions, syrups, elixirs, emulsions and solutions); or solid carriers such as, for example, starches, sugars, kaolin, diluents, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Oral administration is preferred because of its ease of administration, and tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. For parenteral compositions, the carrier will typically comprise sterile water, at least in a major part, although other ingredients may also be included, for example to aid dissolution. For example, injectable solutions may be prepared in which the carrier comprises a salt solution, a glucose solution or a mixture of salt and glucose solutions. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations. In compositions suitable for transdermal administration, the carrier optionally includes a penetration enhancer and/or a suitable wetting agent, optionally in combination with minor proportions of additives of any nature suitable for not introducing significant deleterious effects to the skin. The additives may aid in dermal administration and/or may aid in the preparation of the desired composition. These compositions may be administered in various ways, for example as transdermal patches, drops, ointments.

It is particularly advantageous to formulate the above pharmaceutical compositions in unit dosage form for ease of administration and uniformity of dosage. Unit dosage form as used herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such unit dosage forms are tablets (including scored or coated tablets), capsules, pills, powder product pouches, wafers, suppositories, injectable solutions or suspensions, and the like, as well as multiples thereof.

The exact dosage and frequency of administration will depend upon the particular compound of formula (I) used, the particular condition being treated, the severity of the condition being treated, the age, weight, sex, extent of disorder and general physiological condition of the particular patient, and other drugs the individual may be taking, as is well known to those skilled in the art. Furthermore, it will be apparent that the effective daily amount may be reduced or increased based on the response of the subject being treated and/or based on the evaluation of the physician prescribing the compounds of the instant invention.

Depending on the mode of administration, the pharmaceutical composition will comprise from 0.05% to 99% by weight, preferably from 0.1% to 70% by weight, more preferably from 0.1% to 50% by weight of the active ingredient, and from 1% to 99.95% by weight, preferably from 30% to 99.9% by weight, more preferably from 50% to 99.9% by weight of a pharmaceutically acceptable carrier, all percentages being based on the total weight of the composition.

As already mentioned, the present invention also relates to a pharmaceutical composition comprising a compound according to the present invention and one or more other drugs in the treatment, prevention, control, alleviation or reduction of the risk of a disease or condition for which a compound of formula (I) or other drug may have utility, and the use of such a composition for the preparation of a medicament. The invention also relates to a combination of a compound according to the invention and an mGluR2 positive agonist. The invention also relates to such a combination for use as a medicament. The invention also relates to a product comprising: (a) the compound according to the present invention, a pharmaceutically acceptable salt thereof or a solvate thereof, and (b) an mGluR2 positive agonist, as a combined preparation for simultaneous, separate or sequential use in the treatment or prevention of a condition in a mammal, including a human, which treatment or prevention is affected or facilitated by the neuromodulatory effect of mGluR2 allosteric modulators, particularly positive mGluR2 allosteric modulators. The different drugs of such combinations or products may be combined together in a single formulation with a pharmaceutically acceptable carrier or diluent, or they may both be present in separate formulations with a pharmaceutically acceptable carrier or diluent.

The following examples are given for illustration and are not intended to limit the scope of the invention.

Chemistry

Several methods for preparing the compounds of the present invention are illustrated in the following examples. Unless otherwise stated, all starting materials were obtained from commercial suppliers and used without further purification.

Hereinafter, "THF" means tetrahydrofuran; "DMF" refers to N, N-dimethylformamide; "EtOAc" refers to ethyl acetate; "DCM" means dichloromethane; "DME" means 1, 2-dimethoxyethane; "DCE" means 1, 2-dichloroethane; "DIPE" refers to diisopropyl ether; "DMSO" refers to dimethylsulfoxide; "BINAP" means [1,1 '-binaphthalene ] -2, 2' -bis [ diphenylphosphine ]; "DBU" means 1, 8-diaza-7-bicyclo [5.4.0] undecene; xantphos represents (9, 9-dimethyl-9H-xanthene-4, 5-diyl) bis [ diphenylphosphine ]; MeOH for methanol; "q.s." means sufficient; "m.p." means melting point.

In a single mode reactor: initiator Sixty EXP microwave reactor (Biotage AB) or in a multimodal reactor: the microwave-assisted reaction was carried out in MicroSYNTH Labstation (Milestone, Inc.).

Description 1

4-benzyloxy-1-cyclopropylmethyl-1H-pyridin-2-one (D1)

Bromomethylcyclopropane (3.68 g, 27.33 mmol) and potassium carbonate (10.3 g, 74.52mmol) were added to a solution of 4-benzyloxy-1H-pyridin-2-one (5.0 g, 24.84 mmol) in acetonitrile (200 ml) and the mixture was heated at reflux for 16H. The reaction mixture was filtered through celite and concentrated in vacuo. The crude residue was then triturated with diethyl ether to give pure D1 (6.32 g, 98%) as a white solid.

Description 2

1-Cyclopropylmethyl-4-hydroxy-1H-pyridin-2-one (D2)

A mixture of intermediate D1 (2.0 g, 7.83 mmol) in ethanol (300 ml) and a catalytic amount of 10% palladium on activated carbon was stirred under a hydrogen atmosphere for 2 hours. The mixture was filtered through celite, and the solvent was evaporated in vacuo to yield intermediate D2 (1.3 g, 100%) which was used without further purification.

Description 3

4-bromo-1-cyclopropylmethyl-1H-pyridin-2-one (D3)

Phosphorus tribromide oxide (5.4 g, 18.9 mmol) was added to a solution of intermediate D2 (1.42 g,8.6 mmol) in DMF (140 ml) and the mixture was heated at 110 ℃ for 1 h. After cooling in an ice bath, the solution was partitioned between water and EtOAc. After extraction three times with EtOAc, it is dried (Na)₂SO₄) The combined organic fractions were fractionated and the solvent was evaporated in vacuo. The crude product was purified by column chromatography (silica; DCM as eluent). The desired fractions were collected and evaporated in vacuo to yield intermediate D3 (1.82 g, 93%).

Description 7

4-bromo-1- (3-methylbutyl) -1H-pyridin-2-one (D7)

Intermediate D7 was prepared following the same procedure as carried out for the synthesis of D3, using 4-hydroxy-1- (3-methylbutyl) -1H-pyridin-2-one as starting material by the same method as used for the synthesis of intermediate D2, by reacting 4-benzyloxy-1H-pyridin-2-one with 1-bromo-3-methylbutane.

Description 4

4-benzyloxy-1-butyl-1H-pyridin-2-one (D4)

1-bromobutane (3.75 g, 27.33 mmol) and potassium carbonate (10.3 g, 74.52mmol) were added to a solution of 4-benzyloxy-1H-pyridin-2-one (5.0 g, 24.84 mmol) in acetonitrile (200 ml) and the mixture was heated at reflux for 16H. The reaction mixture was filtered through celite and concentrated in vacuo. The crude residue was then triturated with diethyl ether to obtain pure D4 (6.26 g, 98%) as a white solid.

Description 5

1-butyl-4-hydroxy-1H-pyridin-2-one (D5)

A mixture of intermediate D4 (2.01 g, 7.83 mmol) in ethanol (300 ml) and a catalytic amount of 10% palladium on charcoal was stirred under a hydrogen atmosphere for 2 hours. The mixture was filtered through celite and the solvent was evaporated in vacuo to yield intermediate D5 (1.3 g, 100%) which was used without further purification.

Description 6

4-bromo-1-butyl-1H-pyridin-2-one (D6)

Phosphorus tribromide oxide (5.4 g, 18.9 mmol) was added to a solution of intermediate D5 (1.44 g,8.6 mmol) in DMF (140 ml) and the mixture was heated at 110 ℃ for 1 h. After cooling in an ice bath, the solution was partitioned between water and EtOAc. After three extractions with EtOAc, it was dried (Na)₂SO₄) The organic fractions were combined and the solvent was evaporated in vacuo. By column chromatography (silica gel)(ii) a DCM as eluent) to purify the crude product. The desired fractions were collected and evaporated in vacuo to yield intermediate D6 (1.82 g, 93%).

Description 8

1-butyl-3-chloro-4-hydroxy-1H-pyridin-2-one (D8)

N-chlorosuccinimide (1.6 g, 11.96 mmol) was added to a solution of intermediate D5 (2.0 g, 11.96 mmol) in DMF (30 ml). The reaction was stirred at room temperature overnight and then concentrated in vacuo. The crude product was purified by column chromatography (silica; 0-5% methanol/DCM as eluent) to give intermediate D8 (2.0 g, 83%).

Description 9

Trifluoro-methanesulfonic acid 1-butyl-3-chloro-2-oxo-1, 2-dihydropyridin-4-yl ester (D9)

Pyridine (1.60 ml, 19.8 mmol) was added to a cooled (-78 ℃ C.) solution of intermediate D8 (2.0 g, 9.92 mmol) in DCM (80 ml). The resulting solution was stirred for 10 minutes, after which triflic anhydride (1.90 ml, 10.9 mmol) was added and the resulting solution was stirred at-78 ℃ for 3 hours. The mixture was then warmed to room temperature and quenched by the addition of aqueous saturated ammonium chloride. The mixture was diluted with water, extracted with DCM and dried (Na)₂SO₄) And the solvent was evaporated in vacuo to give crude intermediate D9 (3.31 g, 100%) which was used without further purification.

Description of the preferred embodiments 10

4-benzyloxy-1-cyclopropylmethyl-3-iodo-1H-pyridin-2-one (D10)

N-iodosuccinimide (2.64 g, 11.74 mmol) was added to a solution of intermediate D1 (3.0 g, 11.74 mmol) in acetic acid (40 ml). The reaction mixture was stirred at room temperature for 1 hour, then concentrated in vacuo, purified by flash chromatography (silica; 0-3% methanol/DCM as eluent), and finally recrystallized from diethyl ether to yield intermediate D10 (4.12 g, 92%) as a solid.

Description of the preferred embodiments 11

4-benzyloxy-1-cyclopropylmethyl-3-trifluoromethyl-1H-pyridin-2-one (D11)

Methyl 2, 2-difluoro-2- (fluorosulfonyl) acetate (0.67 ml, 5.24 mmol) and intermediate D10 (1.0 g, 2.63 mmol) were added to a solution of copper (I) iodide (0.99 g, 5.24 mmol) in DMF (30 ml). The mixture was then heated at 100 ℃ for 5 hours before being filtered through celite and the filtrate was concentrated in vacuo. The residue was purified by column chromatography (silica; DCM as eluent) to yield intermediate D11 (0.76 g, 89%).

Description of the preferred embodiments 12

1-Cyclopropylmethyl-4-hydroxy-3-trifluoromethyl-1H-pyridin-2-one (D12)

A mixture of intermediate D11 (2.0 g, 6.19 mmol), a catalytic amount of 10% palladium on activated carbon and ethanol (60 ml) was stirred under an atmosphere of hydrogen for 2 hours. The mixture was filtered through celite, and the solvent was evaporated in vacuo to give crude intermediate D12 (1.45 g, 100%) which was used without further purification.

Description 13

4-bromo-1-cyclopropylmethyl-3-trifluoromethyl-1H-pyridin-2-one (D13)

Phosphorus tribromide oxide (7.03 g, 24.5 mmol) was added to a solution of intermediate D12 (2.60 g, 11.1 mmol) in DMF (50 ml) and the mixture was heated at 110 ℃ for 1 h. After cooling in an ice bath, the solution was partitioned between water and EtOAc. After extraction three times with EtOAc, it is dried (Na)₂SO₄) The organic fractions were combined and the solvent was evaporated in vacuo. The crude product was purified by column chromatography (silica; DCM as eluent). The desired fractions were collected and evaporated in vacuo to yield intermediate D13 (1.38 g, 42%).

Description 14

4-benzyloxy-1- (4-trifluoromethoxy-benzyl) -1H-pyridin-2-one (D14)

1-bromomethyl-4-trifluoromethoxybenzene (3.32 g, 13.04 mmol) and potassium carbonate (3.51 g, 25.46 mmol) were added to a mixture of 4-benzyloxy-1H-pyridin-2-one (2.5 g, 12.42 mmol) in acetonitrile (10 ml). The reaction mixture was heated at reflux temperature for 24 hours. After cooling to room temperature, the solid residue was filtered through celite, washed with methanol, and the combined organic extracts were evaporated in vacuo. The crude residue thus obtained was precipitated with DIPE to yield intermediate D14 (4.5 g, 96%) as a white solid.

Description of the preferred embodiments 15

4-benzyloxy-3-chloro-1- (4-trifluoromethoxy-benzyl) -1H-pyridin-2-one (D15)

N-chlorosuccinimide (1.68 g, 12.61 mmol) was added to a solution of intermediate D14 (4.31 g, 11.47 mmol) in DMF (30 ml) and the mixture was stirred at room temperature for 24 h. The solvent was evaporated and the solid residue was washed with water (4X 25 ml). The crude solid was washed with DIPE to yield intermediate D15 (4.5 g, 95%) as a white solid.

Description 16

3-chloro-4-hydroxy-1- (4-trifluoromethoxy-benzyl) -1H-pyridin-2-one (D16)

Hydrobromic acid (0.1 ml) was added to a mixture of intermediate D15 (4.5 g, 10.98 mmol) in acetic acid (20 ml). The solution was heated at 130 ℃ for 30 minutes under microwave irradiation. After cooling to room temperature, the solvent was evaporated under vacuum and treated with NaHCO₃Until the solution reaches a pH of about 8. The precipitated white solid was collected by filtration and washed with cold DIPE to yield intermediate D16 (1.1 g, 31%).

Description of the preferred embodiments 17

4-bromo-3-chloro-1- (4-trifluoromethoxy-benzyl) -1H-pyridin-2-one (D17)

To tribromidePhosphorus oxide (1.05 g, 3.75 mmol) was added to a solution of intermediate D16 (1.0 g, 3.13 mmol) in DMF (5 ml) and the mixture was heated at 115 ℃ for 4 h. The solvent was evaporated in vacuo and NaHCO₃The crude residue was treated with a saturated aqueous solution of (b). The mixture was extracted with DCM (3X 5 ml) and dried (Na)₂SO₄) Organic portion, and solvent was evaporated in vacuo. The crude product was purified by column chromatography (silica gel; diethyl ether as eluent). The desired fractions were collected and evaporated in vacuo to yield intermediate D17 (0.21 g, 18%) as a yellow oil.

Description 18

1 '-Cyclopropylmethyl-4-phenyl-3, 4,5, 6-tetrahydro-2H, 1' H- [1,4 '] bipyridinyl-2' -one (D18)

4-phenylpiperidine (0.45 g, 2.78 mmol), palladium (II) acetate (0.016 g, 0.069 mmol), sodium tert-butoxide (0.34 g, 3.5 mmol) and BINAP (0.065 g, 0.104 mmol) were added to a solution of intermediate D3 (0.32 g, 1.39 mmol) in toluene (5 ml). The reaction mixture was heated in a sealed tube at 100 ℃ for 16 h, then cooled to room temperature, diluted with water (5 ml) and extracted with EtOAc (3 × 5 ml). Drying (Na)₂SO₄) The organic fractions were combined and the solvent was evaporated in vacuo. The crude product was purified by column chromatography (silica gel; 0-4% methanol/DCM as eluent). The desired fractions were collected and evaporated in vacuo to yield intermediate D18 (0.33 g, 78%).

Description 19

1 '-butyl-4-phenyl-3, 4,5, 6-tetrahydro-2H, 1' H- [1,4 '] bipyridinyl-2' -one (19)

4-phenylpiperidine (0.45 g, 2.78 mmol), palladium (II) acetate (0.016 g, 0.069 mmol), sodium tert-butoxide (0.34 g, 3.5 mmol) and BINAP (0.065 g, 0.104 mmol) were added to a solution of intermediate D6 (0.32 g, 1.39 mmol) in toluene (5 ml). The reaction mixture was heated in a sealed tube at 100 ℃ for 16 h, then cooled to room temperature, then diluted with water (5 ml) and extracted with EtOAc (3 × 5 ml). Drying (Na)₂SO₄) The organic fractions were combined and the solvent was evaporated under vacuum. The crude product was purified by column chromatography (silica gel; 0-4% methanol/DCM as eluent). The desired fractions were collected and evaporated in vacuo to yield intermediate D19 (0.38 g, 89%).

Description 20

1 ' -Cyclopropylmethyl-2 ' -oxo-4-phenyl-3, 4,5,6,1 ', 2 ' -hexahydro-2H- [1,4 ' ] bipyridinyl-4-carbonitrile (D20) JNJ-38818468

4-cyano-4-phenylpiperidine hydrochloride (0.314 g, 1.41 mmol), palladium (II) acetate (0.013 g, 0.059 mmol), sodium tert-butoxide (0.347 g, 3.54 mmol) and BINAP (0.051 g, 0.08 mmol) were added to a stirred solution of intermediate D3 (0.27 g, 1.18 mmol) in toluene (5 ml). The reaction mixture was heated in a sealed tube at 100 ℃ for 16 h, after cooling to room temperature, the mixture was diluted with water and extracted with EtOAc. Drying (Na)₂SO₄) The organic fractions were combined and the solvent was evaporated under vacuum. The crude product was purified by column chromatography (silica gel; 10% ammonia in methanol (7M) in DCM as eluent). The desired fractions were collected and evaporated in vacuo to yield intermediate D20 (0.35 g, 87%) as a pale yellow oil.

Description of the preferred embodiments 21

4-hydroxy-4-phenylpiperidine-1-carboxylic acid tert-butyl ester (D21)

Methyl 2-bromobenzoate (1.816 ml, 12.936 mmol) [ CAS610-94-6 ]]1,2,3, 6-tetrahydro-4- (4,4,5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) pyridine (4 g, 12.936 mmol) [ CAS375853-82-0 mmol ] added to 1, 4-dioxane (28 ml)](Synthesis described in WO2004072025A 220040826) and NaHCO₃To a saturated aqueous solution (24 ml). The resulting solution was degassed using a nitrogen stream and Pd (PPh)₃)₄(0.747 g, 0.647 mmol) was added to the solution. Then, the reaction was treated with microwaves at 140 ℃ for 5 minutes in a sealed tube. The resulting cooled reaction mixture was then diluted with EtOAc and filtered through a celite pad. Collecting the filtrate, passing through Na₂SO₄Dried and concentrated in vacuo. The crude reaction mixture was then purified by column chromatography (silica gel; DCM to DCM/EtOAc to 6% as eluent). The desired fractions were collected and evaporated in vacuo to yield D21 (4.04 g, 98%).

Description of the preferred embodiments 22

4- (2-fluoro-4-methoxycarbonyl-phenyl) -3, 6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester (D22)

Methyl 4-bromo-3-fluorobenzoate (2.261 g, 9.702 mmol) [ CAS849758-12-9 ]]1,2,3, 6-tetrahydro-4- (4,4,5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) pyridine (3 g, 9.702 mmol) [ CAS375853-82-0 mmol ] added to 1, 4-dioxane (21 ml)](the synthesis is described in WO2004072025A 220040826) and NaHCO₃To a saturated aqueous solution (18 ml). The resulting solution was degassed using a nitrogen stream and Pd (PPh)₃)₄(0.561 g, 0.485 mmol) was added to the solutionIn (1). Then, the reaction was treated with microwaves at 150 ℃ for 5 minutes in a sealed tube. The resulting cooled reaction mixture was then diluted with EtOAc and filtered through a celite pad. Collecting the filtrate, passing through Na₂SO₄Dried and concentrated in vacuo. The crude reaction mixture was then purified by column chromatography (silica gel; DCM to DCM/EtOAc to 6% as eluent). The desired fractions were collected and evaporated in vacuo to yield D22 (2.107 g, 65%).

Description 23

4- (2-fluoro-4-methoxycarbonyl-phenyl) -piperidine-1-carboxylic acid tert-butyl ester (D23)

A solution of intermediate D22 (2.81 g, 8.379 mmol) in methanol (120 ml) was hydrogenated in the presence of 10% palladium on activated carbon (0.588 g) at room temperature until the reaction was complete. The solid was filtered off and the filtrate was evaporated in vacuo to give D23 (2.73 g, 97%).

Description 24

4- [ 2-fluoro-4- (1-hydroxy-1-methyl-ethyl) -phenyl ] piperidine-1-carboxylic acid tert-butyl ester (D24)

A solution of 1.4M methylmagnesium bromide in toluene/THF (17.339 ml, 24.274 mmol) was added dropwise to a cooled (0 ℃) solution of intermediate D23 (2.73 g, 8.091 mmol) in diethyl ether (150 ml) under a hydrogen atmosphere. The resulting reaction mixture was then stirred at 50 ℃ for 2 hours. After cooling in an ice bath, the mixture was carefully quenched with a saturated aqueous solution of ammonium chloride and then extracted with EtOAc. Drying (Na)₂SO₄) The combined organic phases and the solvent was evaporated in vacuo to yieldD24（3.16g，100%）。

Description 25

2- (3-fluoro-1-piperidin-4-yl-phenyl) -propan-2-ol (D25)

A mixture of intermediate D24 (3.067 g, 7.852 mmol) and KOH (2.54 g, 45.268 mmol) in isopropanol (13.5 ml) and water (27 ml) was microwaved at 180 ℃ for 60 minutes in a sealed tube. The resulting cooled reaction mixture was then diluted with water and brine and extracted with dichloromethane. Drying (Na)₂SO₄) The organic extracts were combined and the solvent was evaporated in vacuo. The residue was treated with dichloromethane to give a filtered solid to obtain 1.03g of intermediate D25. The filtrate is evaporated in vacuo and then purified by column chromatography (silica; DCM/(NH in MeOH)₃7N solution) up to a gradient of 10% as eluent) to purify the residue thus obtained. The desired fractions were collected and evaporated in vacuo to yield a second batch of 0.5g of D25 (total =1.53g, 82%). M.p.151 ℃.

Description 26

4- (2-Methoxycarbonylphenyl) -piperidine-1-carboxylic acid tert-butyl ester (D26)

A solution of intermediate D21 (4.04 g, 12.729 mmol) in methanol (120 ml) was hydrogenated in the presence of 10% palladium on activated carbon (0.846 g) at room temperature until the reaction was complete. The solid was filtered off and the filtrate was evaporated in vacuo to give D26 (3.67 g, 90%) as a white solid.

Description 27

4- [2- (1-hydroxy-1-methyl-ethyl) -phenyl ] -piperidine-1-carboxylic acid tert-butyl ester (D27)

A solution of 1.4M methylmagnesium bromide in toluene/THF (17.443 ml, 24.421 mmol) was added dropwise to a cooled (0 ℃) solution of intermediate D26 (2.6 g, 8.14 mmol) in diethyl ether (150 ml) under a hydrogen atmosphere. The resulting reaction mixture was stirred at 45 ℃ for 2 hours. After cooling in an ice bath, the mixture was carefully quenched with a saturated aqueous solution of ammonium chloride and then extracted with EtOAc. Drying (Na)₂SO₄) The organic phases were combined and the solvent was evaporated in vacuo to yield D27 (2.77 g, 69%).

Description of the preferred embodiments 28

2- (2-piperidin-4-yl-phenyl) -propan-2-ol (D28)

A mixture of intermediate D27 (2.77 g, 5.636 mmol) and KOH (2.43 g, 43.357 mmol) in isopropanol (13.5 ml) and water (27 ml) was microwaved in a sealed tube at 180 ℃ for 60 minutes. The resulting cooled reaction mixture was then diluted with water and brine and extracted with dichloromethane. The residue was treated with dichloromethane to yield a filtered solid. Yield: 0.737g of intermediate D28. The filtrate is evaporated in vacuo and then purified by column chromatography (silica; DCM/(NH in MeOH)₃7N solution) gradient to 10% as eluent) to purify the residue. The desired fractions were collected and evaporated in vacuo to yield a second batch of 0.306g of intermediate D28 (total =1.04g, 84%). M.p.219.5 ℃.

Description 29

4-hydroxy-4-phenylpiperidine-1-carboxylic acid tert-butyl ester (D29)

Di-tert-butyl dicarbonate (2.95 g, 13.53 mmol) was added to a solution of 4-hydroxy-4-phenylpiperidine (2 g, 11.28 mmol) in DCM (50 ml). The reaction was stirred at room temperature for 5 hours. Removal of the solvent under vacuum provided the desired crude intermediate D29 (3.12 g, 100%) which was used without further purification.

Description of the preferred embodiments 30

4-fluoro-4-phenylpiperidine-1-carboxylic acid tert-butyl ester (D30)

In N₂A solution of (diethylamino) sulphur trifluoride (0.74 ml, 5.67 mmol) in dry DCM (q.s.) was added to a cooled (-78 ℃ C.) solution of D29 (1.5 g, 5.4 mmol) in dry DCM (30 ml) under an atmosphere. After the addition was complete, the reaction mixture was stirred at-78 ℃ for 1 hour, then allowed to reach room temperature and stirred for an additional 30 minutes. Saturated NaHCO was added₃Aqueous solution (90 ml), and the mixture was stirred for 15 minutes, and then the organic layer was separated. Thereafter, 3-chloroperoxybenzoic acid (0.2 g, 1.18 mmol) was added, and the reaction was stirred at room temperature for 30 minutes. Saturated with aqueous NaHCO₃The reaction mixture was washed with water and brine, and then with Na₂SO₄Drying, filtration, and concentration in vacuo afforded the desired crude intermediate D30 (1.48 g, 98%), which was used without further purification.

Description 31

4-fluoro-4-phenylpiperidine hydrochloride (D31)

D30 (1.48 g, 5.29 mmol) was dissolved in 4N HCl in dioxane. The reaction was stirred at room temperature for 2 hours. The solvent is removed. The crude product was triturated with diethyl ether and dried in vacuo to afford the desired intermediate D31 (1.10 g, 97%) as the hydrochloride salt, which was used without further purification.

Description 32

1 ' -butyl-4-fluoro-4-phenyl-3, 4,5, 6-tetrahydro-2H, 1 ' H- [1,4 ' ] bipyridinyl-2-one (D32)

D31 (0.2 g, 0.94 mmol), palladium (II) acetate (0.009 g, 0.04 mmol), sodium tert-butoxide (0.25 g, 2.58 mmol) and BINAP (0.037 g, 0.06 mmol) were added to a stirred solution of intermediate D6 (0.20 g, 0.86 mmol) in toluene (5 ml). The reaction mixture was heated in a sealed tube at 100 ℃ for 16 hours. After cooling to room temperature, the mixture was diluted with water and extracted with EtOAc. Drying (Na)₂SO₄) The organic phases were combined and the solvent was evaporated in vacuo. The crude product was purified by column chromatography (silica gel; 10% ammonia in methanol (7N) as eluent). The desired fractions were collected and evaporated in vacuo to yield D32 (0.21 g, 87%) as a pale yellow oil.

Description 33

4-benzyloxy-3-bromo-1-cyclopropylmethyl-1H-pyridin-2-one (D33)

A solution of intermediate D1 (3.0 g, 11.7 mmol) and N-bromosuccinimide (2.09 g, 11.7 mmol) in DCM (100 ml) was stirred for 1h at room temperature. The solvent was evaporated under vacuum and the crude residue was purified by column chromatography (silica; DCM as eluent). The desired fractions were collected and evaporated in vacuo to yield D33 (3.56 g, 91%).

Description 34

4-benzyloxy-3-cyclopropyl-1-cyclopropylmethyl-1H-pyridin-2-one (D34)

NaHCO is added₃(1.0 g, excess), cyclopropylboronic acid (0.74 g, 8.93 mmol), potassium carbonate (1.23 g, 8.93 mmol) and [1, 1' -bis (diphenylphosphino) ferrocene]Palladium (II) dichloride-DCM complex (0.36 g, 0.45 mmol) was added to a solution of intermediate D10 (1.0 g, 2.98 mmol) in 1, 4-dioxane (10 ml). The resulting mixture was heated under microwave irradiation at 175 ℃ for 20 minutes, after which it was filtered through celite and the solvent was evaporated in vacuo. The crude residue was purified by column chromatography (silica gel; 0-3% methanol/DCM as eluent). The desired fractions were collected and evaporated in vacuo to yield D34 (0.6 g, 69%).

Description 35

3-cyclopropyl-1-cyclopropylmethyl-4-hydroxy-1H-pyridin-2-one (D35)

A mixture of intermediate D34 (1.0 g, 3.38 mmol) in ethanol (150 ml) and a catalytic amount of 10% palladium on activated carbon was stirred under a hydrogen atmosphere for 2 hours. The mixture was filtered through celite, and the solvent was evaporated in vacuo to yield intermediate D35 (0.69 g, 100%) which was used without further purification.

Description 36

4-bromo-3-cyclopropyl-1-cyclopropylmethyl-1H-pyridin-2-one (D36)

Phosphorus tribromide oxide (2.4 g, 8.28 mmol) was added to a solution of intermediate D35 (0.85 g, 4.14 mmol) in DMF (60 ml) and the mixture was heated at 110 ℃ for 1 h. After cooling in an ice bath, the solution was partitioned between water and EtOAc. Extracted with EtOAc (3X 200 ml) and dried (Na)₂SO₄) The organic fractions were combined and the solvent was evaporated in vacuo. The crude product was purified by column chromatography (silica; DCM as eluent). The desired fractions were collected and evaporated in vacuo to yield intermediate D36 (0.99 g, 89%).

Description 37

4- (1 ' -Cyclopropylmethyl-2 ' -oxo-3, 4,5,6,1 ', 2 ' -hexahydro-2H- [1,4 ' ] bipyridinyl-4-yl) benzoic acid (D37)

Methyl 4-piperidine-4-benzoate (0.40 g, 1.81 mmol), palladium (II) acetate (0.015 g, 0.069 mmol), sodium tert-butoxide (0.34 g, 3.44 mmol) and BINAP (0.06 g, 0.096 mmol) were added to a stirred solution of intermediate D3 (0.31 g, 1.37 mmol) in toluene (10 ml). The reaction mixture was heated in a sealed tube at 100 ℃ for 16 hours. After cooling to room temperature, the mixture was diluted with EtOAc, then filtered through celite, after which the solvent was evaporated in vacuo. The crude residue was treated with a mixture of DCM/methanol and then filtered off. The filtrate was evaporated to dryness in vacuo to give crude D37 (0.48 g, 100%), which was used without further purification.

Description 38

Methyl 4- (1 ' -cyclopropylmethyl-2 ' -oxo-3, 4,5,6,1 ', 2 ' -hexahydro-2H- [1,4 ' ] bipyridinyl-4-yl) benzoate (D38)

A mixture of intermediate D37 (0.43 g, 1.23 mmol), DBU (0.18 g, 1.23 mmol), dimethyl carbonate (4.5 ml, excess, 93 mmol) and acetonitrile (5 ml) was heated under microwave radiation at 160 ℃ for 20 min. The cooled crude mixture was diluted with water and EtOAc was added, after which the organic layer was washed with 10% aqueous citric acid and dried (Na)₂SO₄) And the solvent was evaporated in vacuo. The crude residue was purified by column chromatography (silica gel; 0-3% methanol/DCM as eluent). The desired fractions were collected and evaporated in vacuo to yield D38 (0.19 g, 38%).

Description 39

1 '-Cyclopropylmethyl-4- [4- (1-hydroxy-1-methyl-ethyl) -phenyl ] -3,4,5, 6-tetrahydro-2H, 1' H- [1,4 '] bipyridinyl-2' -one (D39)

A solution of 1.4M methylmagnesium bromide in toluene/THF (1.12 ml, 1.57 mmol) was added dropwise to a cooled (0 ℃ C.) solution of intermediate D38 (0.19 g, 0.52 mmol) in THF (20 ml) under a nitrogen atmosphere. The resulting reaction mixture was stirred at 45 ℃ for 2 hours. After cooling in an ice bath, the mixture was carefully quenched with a saturated aqueous solution of ammonium chloride and then extracted with EtOAc. Drying (Na)₂SO₄) The organic phases were combined and the solvent was evaporated in vacuo. The residue was purified by column chromatography (silica gel; 0-5% methanol/DCM as eluent). The desired fractions were collected and evaporated in vacuo to yield D39 (0.077 g, 40%) as an oil.

Example 1

3 ' -chloro-1 ' -cyclopropylmethyl-4-phenyl-3, 4,5, 6-tetrahydro-2H, 1 ' H- [1,4 ' ] bipyridinyl-2 ' -one (E1)

A solution of intermediate D18 (0.2 g, 0.65 mmol) and N-chlorosuccinimide (0.09 g, 0.65 mmol) in DCM (10 ml) was stirred at room temperature for 1 h. The solvent was evaporated in vacuo and the crude product was purified by column chromatography (silica; 0-3% methanol in DCM as eluent). The desired fractions were collected and evaporated in vacuo, then the resulting solid was recrystallized from diethyl ether to yield compound E1 (0.10 g, 47%) as a white solid.

Melting point: 170.8 ℃.

¹HNMR(400MHz,CDCl₃)ppm0.35-0.42(m,2H),0.57-0.64(m,2H)，1.19-1.33(m,1H),1.85-2.00(m,4H)，2.64-2.76(m,1H),2.85-2.99(m,2H),3.76-3.87(m,4H),6.05(d,J=7.6Hz,1H),7.19-7.29(m,4H),7.29-7.38(m,2H).

Example 2

1 ' -butyl-3 ' -chloro-4-phenyl-3, 4,5, 6-tetrahydro-2H, 1 ' H- [1,4 ' ] bipyridinyl-2 ' -one (E2)

A solution of intermediate D19 (0.43 g, 0.65 mmol) and N-chlorosuccinimide (0.19 g, 1.40 mmol) in DCM (10 ml) was stirred at room temperature for 1 h. The solvent was evaporated in vacuo and the crude product was purified by column chromatography (silica; 0-3% methanol in DCM as eluent). The desired fractions were collected and evaporated in vacuo, then the resulting solid was recrystallized from diethyl ether to yield compound E2 (0.39 g, 82%) as a white solid.

Melting point: 149.4 ℃.

¹HNMR(400MHz,CDCl₃)ppm0.95(t，J=7.3HZ，3H),1.31-1.42(m,2H),1.68-1.78(m,2H),1.85-1.98(m，4H)，2.64-2.73(m,1H),2.87-2.96(m,2H),3.82(br d,J=12.1Hz，2H),3.93(t,J=7.3Hz，2H),6.03(d,J=7.6Hz,1H),7.10(d,J=7.6Hz，1H),7.19-7.28(m,3H),7.29-7.37(m,2H)

Example 3

3 ' -bromo-1 ' -cyclopropylmethyl-4-phenyl-3, 4,5, 6-tetrahydro-2H, 1 ' H- [1,4 ' ] bipyridinyl-2 ' -one (E3)

N-bromosuccinimide (0.145 g, 0.82 mmol) was added to a solution of intermediate D18 (0.25 g, 0.82 mmol) in DCM (10 ml). The reaction mixture was stirred at room temperature for 1 hour. Subsequently, the solvent was evaporated in vacuo and the crude residue was purified by column chromatography (silica; 0-3% methanol/DCM as eluent). The desired fractions were collected and evaporated in vacuo to yield compound E3 (0.20 g, 64%) as a white solid.

Melting point: 150 ℃.

¹HNMR(500MHz,DMSO-d₆)ppm0.34-0.40(m,2H),0.44-0.50(m,2H),1.16-1.26(m,1H),1.77(qd，J=12.38,3.61Hz,2H),1.88(br d,J=12.1Hz,2H）,2.68-2.78(m,1H),2.91(br t,J=11.9Hz,2H)3.69(br d,J=12.1Hz,2H),374(d,J=7.2Hz,2H),6.21(d,J=7.5Hz,1H),7.19-7.25(m,1H),7.27-7.36(m，4H),7.69(d,J=7.5Hz,1H).

Example 4

1 ' -Cyclopropylmethyl-4-phenyl-3 ' -trifluoromethyl-3, 4,5, 6-tetrahydro-2H, 1 ' H- [1,4 ' ] bipyridinyl-2 ' -one (E4)

4-phenylpiperidine (0.33 g, 2.02 mmol), palladium (II) acetate (0.012 g, 0.05 mmol), sodium tert-butoxide (0.24 g, 2.52 mmol) and BINAP (0.05 g, 0.08 mmol) were added to a solution of intermediate D13 (0.3 g, 1.01 mmol) in toluene (7 ml). The reaction mixture was heated in a sealed tube at 100 ℃ for 16 h, then cooled to room temperature, then diluted with water (5 ml) and extracted with EtOAc (3 × 5 ml). Drying (Na)₂SO₄) The organic fractions were combined and the solvent was evaporated in vacuo. The crude product was purified by column chromatography (silica gel; 0-4% methanol/DCM as eluent). The desired fractions were collected and evaporated in vacuo to yield compound E4 (0.11 g, 31%) as a white solid.

Melting point: 177.2 ℃.

¹HNMR(500MHz,DMSO-d₆)ppm0.33-0.38(m,2H),0.45-0.50(m,2H),1.13-1.22(m,1H),1.64-1.75(m,2H)，1.84(br d,J=11.0Hz,2H)，2.72-2.80(m,1H),3.14(br t,J＝12.1Hz,2H),3.59(br d,J=13.0Hz,2H),3.65(d,J=7.2Hz,2H),6.21(d,J=7.8Hz,1H),7.19-7.23m,1H)，7.24-7.29(m,2H),7.29-7.34(m,2H),7.73(d,J=7.8Hz,1H).

Example 5

3 ' -chloro-4-phenyl-1 ' - (4-trifluoromethoxybenzyl) -3,4,5, 6-tetrahydro-2H, 1 ' H- [1,4 ' ] bipyridinyl-2 ' -one (E5)

A mixture of intermediate D17 (0.2 g, 0.52 mmol), 4-phenylpiperidine (0.1 g, 0.62 mmol), 1- (2' -di-tert-butylphosphine) palladium (II) biphenylacetate (0.01 g, 0.026 mmol) and potassium phosphate (0.23 g, 1.1 mmol) in 1, 4-dioxane (3 ml) was stirred at 90 ℃ for 35 hours. The mixture was filtered through celite and after washing with more 1, 4-dioxane, the filtrate was evaporated to dryness. The crude product was purified by column chromatography (silica gel; heptane/diethyl ether 1:1 as eluent). The desired fractions were collected and evaporated in vacuo to yield compound E5 (0.075 g, 31%) as a white solid.

Melting point: 168.6 ℃.

¹H NMR(400MHz,CDCl₃)ppm1.83-1.98(m,4H),2.65-2.75(m,1H),2.89-2.98(m,2H),3.84(br d,J=12.2Hz,2H),5.12(s,2H),6.06(d,J=7.6Hz,1H),7.14(d,J=7.6Hz,2H),7.15-7.28(m,5H)，7.29-7.40(m,4H).

Example 6

3 '-chloro-1' -cyclopropylmethyl-2 '-oxo-4-phenyl-3, 4,5,6, 1', 2 '-hexahydro-2H- [1, 4' ] bipyridinyl-4-carbonitrile (E6)

A solution of intermediate D20 (0.35 g, 1.03 mmol) and N-chlorosuccinimide (0.14 g, 1.03 mmol) in DCM (25 ml) was stirred at room temperature for 1 h. After addition of more DCM, the solution was washed with brine and dried (Na)₂SO₄) And the solvent was evaporated in vacuo. The crude product was purified by column chromatography (silica gel; mobile phase: 10% ammonia in methanol (7N)/DCM as eluent) and further purified by preparative HPLC. The desired fractions were collected and evaporated in vacuo toCompound E6 (0.17 g, 47%) was produced as a white solid.

Melting point: 173.7 ℃.

¹H NMR(400MHz,DMSO-d₆)ppm0.17-0.23(m，2H),0.26-0.33(m,2H),0.97-1.09(m,1H),1.91-2.02(m,2H),2.11(br d,J=12.9Hz,2H)2.98(br t,J=12.4Hz,2H),3.54-3.63(m，4H),6.14(d,J=7.4Hz,1H),7.20-7.26(m,1H),7.27-7.35(m，2H),7.40-7.44(m,2H),7.52(d,J=7.4Hz,1H).

Example 7

1 ' -butyl-3-chloro-4-fluoro-4-phenyl-3, 4,5, 6-tetrahydro-2H, 1 ' H- [1,4 ' ] bipyridinyl-2-one (E7)

A solution of intermediate D32 (0.21 g, 0.66 mmol) and N-chlorosuccinimide (0.08 g, 0.66 mmol) in DCM (30 ml) was stirred for 10 min at room temperature. After addition of more DCM, the solution was washed with brine and dried (Na)₂SO₄) And the solvent was evaporated in vacuo. The crude product was purified by column chromatography (silica gel; 10% ammonia in methanol (7M) in DCM as eluent) and further purified by preparative HPLC. The desired fractions were collected and evaporated in vacuo to yield compound E7 (0.065 g, 27%) as a white solid.

Melting point: 136.7 ℃.

¹H NMR(400MHz，DMSO-d₆)ppm0.89(t,J＝7.4Hz，3H)，1.21-1.32(m，2H)，1.54-1.64(m，2H)，2.03(t，J＝11.8Hz，2H)，2.16(td，J＝13.9，4.6Hz，lH)，2.26(td，J＝13.6，4.6Hz，1H)，3.17(dd，J＝12.3，11.1Hz，2H)，3.54-3.64(m，2H)，3.87(t，J＝7.2Hz，2H)，6.26(d，J＝7.6Hz，1H)，7.32-7.38(m，1H)，7.42(t，J＝7.4Hz，2H)，7.45-7.51(m，2H)，7.62(d，J＝7.4Hz，1H).

Example 8

3 ' -cyclopropyl-1 ' -cyclopropylmethyl-4-phenyl-3, 4,5, 6-tetrahydro-2H, 1 ' H- [1,4 ' ] bipyridinyl-2 ' -one (E8)

4-phenylpiperidine (0.22 g, 1.34 mmol), palladium (II) acetate (0.008 g, 0.034 mmol), sodium tert-butoxide (0.16 g, 1.68 mmol) and BINAP (0.032 g, 0.05 mmol) were added to a solution of intermediate D36 (0.18 g, 0.67 mmol) in toluene (5 ml). The reaction mixture was heated in a sealed tube at 100 ℃ for 16 h, then cooled to room temperature, then diluted with water (5 ml) and extracted with EtOAc (3 × 5 ml). Drying (Na)₂SO₄) The organic fractions were combined and the solvent was evaporated in vacuo. The crude product was purified by column chromatography (silica gel; 0-4% methanol/DCM as eluent). The desired fractions were collected and evaporated in vacuo to yield compound E8 (0.18 g, 77%) as a white solid.

Melting point: 201.9 ℃.

¹H NMR(500MHz，DMSO-d₆)ppm0.30-0.35(m，2H)0.41-0.47(m，2H)0.74-0.80(m，2H)，0.86-0.92(m，2H)，1.11-1.21(m，1H)，1.60-1.67(m，1H)，1.73-1.89(m，4H)，2.63-2.72(m，1H)，2.87(br t，J＝11.1Hz，2H)，3.57-3.65(m，4H)，6.07(d，J＝7.5Hz，1H)，7.19-7.24(m，1H)，7.26-7.37(m，4H)，7.46(d，J＝7.5Hz，1H).

Example 9

3 ' -chloro-1 ' -cyclopropylmethyl-4- [4- (1-hydroxy-1-methyl-ethyl) -phenyl ] -3,4,5, 6-tetrahydro-2H, 1 ' H- [1,4 ' ] bipyridinyl-2 ' -one (E9)

A solution of intermediate D39 (0.077 g, 0.21 mmol) and N-chlorosuccinimide (0.03 g, 0.21 mmol) in DCM (8 ml) was stirred for 5 min at room temperature. With NaHCO₃The crude mixture was washed with saturated solution, then extracted with DCM and dried (Na)₂SO₄) The organic fractions were combined and the solvent was evaporated in vacuo. The crude residue was purified by column chromatography (silica gel; 0-5% methanol/DCM as eluent). A second column chromatography was performed (silica; DCM/EtOAc1:1, and finally 100% EtOAc as eluent). The desired fractions were collected, then evaporated in vacuo and the resulting solid was crystallized from diethyl ether to yield compound E9 (0.06 g, 71%) as a white solid.

¹H NMR(400MHz,CDCl₃)ppm0.35-0.41(m，2H)，0.56-0.64(m,2H),1.19-1.30(m,1H)，1.59(s,6H),1.73(s,1H),185-1.99(m,4H),2.65-2.76(m,1H),2.87-2.97(m,2H)，3.78-3.87(m,4H),6.05(d,J=7.6Hz，1H),7.21-7.26(m,3H),7.45(d,J=8.3Hz,2H).

Example 20

3 ' -chloro-1 ' -cyclopropylmethyl-4- (2-fluoro-ethoxy) -4-phenyl-3, 4,5, 6-tetrahydro-2H, 1 ' H- [1,4 ' ] bipyridinyl-2 ' -one (E20)

A solution of compound E31 (0.164 g, 0.46 mmol) in 1, 2-dimethoxyethane (3 ml) was added dropwise to a mixture of sodium hydride (0.023 g, 0.58 mmol) in 1, 2-dimethoxyethane (0.5 ml) at 0 ℃. The reaction mixture was stirred at room temperature for 15 minutes and then addedEthyl 2-fluorotosylate (2-fluoroethyl tosylate) [ CAS:383-50-6 ] in 1, 2-dimethoxyethane (1 ml)](0.222 g, 1 mmol). The reaction mixture was microwaved in a sealed tube at 180 ℃ for 20 minutes. The mixture was cooled to room temperature and an additional amount of sodium hydride (0.023 g, 0.58 mmol) was added. The mixture was heated under microwave irradiation at 180 ℃ for 20 minutes. After cooling to room temperature, saturated aqueous ammonium chloride was added and the mixture was extracted with EtOAc. The organic layer was separated and dried (Na)₂SO₄) And the solvent was evaporated. The crude product was first purified by column chromatography (silica gel; eluent: 100/0 to 90/10 DCM/EtOAc). The desired fractions were collected and evaporated in vacuo to yield compound E20 (0.041 g, 18%).

¹H NMR(400MHz，CDCl₃)ppm0.36-0.40(m，2H)，0.58-0.62(m，2H)，1.22-1.28(m，1H)，2.12-2.21(m，4H)，3.27-3.36(m，4H)，3.57(br d，J＝12.1Hz，2H)，3.80(d，J＝7.2Hz，2H)，4.5l(dm，J＝47.7Hz，2H)，6.08(d，J＝7.5Hz，1H)，7.23(d，J＝7.5Hz，1H)，7.29-7.32(m，1H)，7.37-7.41(m，2H)，7.44-7.46(m，2H).

Example 21

3 ' -chloro-1 ' -cyclopropylmethyl-4-fluoromethyl-4-phenyl-3, 4,5, 6-tetrahydro-2H, 1 ' H- [1,4 ' ] bipyridinyl-2 ' -one (E21)

(diethylamino) sulphur trifluoride (0.046 ml, 0.35 mmol) was added to a cooled (-78 ℃ C.) solution of compound E30 (0.119 g, 0.32 mmol) in DCM (1 ml). The reaction mixture was stirred at-78 ℃ for 3 hours, then at 0 ℃ for an additional 2 hours. Subsequently, additional (diethylamino) sulphur trifluoride (0.046 ml, 0.35 mmol) was added and the mixture was stirred at room temperature for a further 1 h. Adding Na₂CO₃(saturated aqueous solution) and the mixture was diluted with DCM. The organic layer was separated and dried (Na)₂SO₄) And evaporated until dry. The crude product was purified by column chromatography (silica gel; eluent: 100/0 to 80/20 DCM/EtOAc). The desired fractions were collected, evaporated in vacuo, and finally freeze-dried to yield compound E21 (0.019 g, 16%) as a white foam.

¹H NMR(400MHz，CDCl₃)ppm0.33-0.40(m，2H)，0.52-0.65(m，2H)，1.17-1.29(m，1H)，1.74-1.96(m，4H)，2.96(d，J＝22.7Hz，2H)，3.06(dt，J＝11.6，3.7Hz，2H)，3.45-3.52(m，2H)，3.79(d，J＝7.2Hz，2H)，6.01(d,J＝7.6Hz，1H)，7.20-7.36(m，6H).

Example 22

1 ' -butyl-3 ' -chloro-4-hydroxymethyl-4-phenyl-3, 4,5, 6-tetrahydro-2H, 1 ' H- [1,4 ' ] bipyridinyl-2 ' -one (E22)

4-hydroxymethyl-4-phenylpiperidine (0.172 g, 0.9 mmol), palladium (II) acetate (0.007 g, 0.03 mmol), caesium carbonate (0.391 g, 1.2 mmol) and Xantphos (0.035 g, 0.06 mmol) were added to a solution of intermediate D9 (0.2 g, 0.6 mmol) in trifluorotoluene (2 ml). The reaction mixture was heated in a sealed tube at 100 ℃ for 24 hours and thereafter cooled to room temperature. Then, with DCM, H₂O (5 ml) diluted and extracted with EtOAc (3X 5 ml). The mixture was filtered through celite, and the filtrate was evaporated to dryness. The crude product was first purified by column chromatography (silica gel; eluent: 90/10 to 0/100 DCM/EtOAc) and then by reverse phase HPLC. The desired fractions were collected, evaporated in vacuo, and finally lyophilized to yield compound E22 (0.041 g, 18%) as a white foam.

¹H NMR(400MHz,CDCl₃)ppm0.93(t,J=7.3Hz,3H),1.13(br t，J=6.7Hz，1H),1.28-1.40(m,2H),1.64-1.75(m,2H),1.98-2.08(m，2H),2,31-2.40(m，2H),2.98-3.10(m,2H)，3.41-3.51(m,2H),3.63(d,J=6.5Hz,2H)，3.90(t,J=7.3Hz,2H),5.92(d,J=7.5Hz,1H),7.04(d,J＝7.5Hz,1H),7.27-7.33(m,1H),7.36-7.46(m，4H).

Example 28

1 ' -butyl-3 ' -chloro-4- [2- (1-hydroxy-1-methyl-ethyl) -phenyl ] -3,4,5, 6-tetrahydro-2H, 1 ' H- [1,4 ' ] bipyridinyl-2 ' -one (E28)

A mixture of intermediate D9 (0.254 g, 0.76 mmol), intermediate D28 (0.2 g, 0.912 mmol) and diisopropylethylamine (0.199 ml, 1.114 mmol) in acetonitrile (11 ml) was heated under microwave irradiation at 180 ℃ for 5 min. The cooled crude mixture was evaporated in vacuo. The crude residue was purified by column chromatography (silica; DCM/EtOAc/MeOH as eluent). The desired fractions were collected and evaporated in vacuo. The solid residue obtained was treated with diisopropyl ether. The solid was filtered to give compound E28 (0.183 g, 61%).

M.P.182°C。

¹H NMR(400MHz,CDCl₃)ppm 0.95(t,J=7.3Hz，3H),1.32-1.42(m,2H),1.70(s,6H)，1.71-1.77(m,2H),1.79(s,1H),1.82-1.90(m，2H),1.91-2.05(m,2H)，2.88-2.98(m,2H)，3.76-3.87(m,3H),3.93(tJ=7.3Hz,2H),6.03(d,J=7.5Hz,1H)，7.11(d,J=7.5Hz,1H),7.16(td,J=7.8，1.4Hz,1H),7.28(td,J=7.4,1.4Hz,1H)，7.41(dd，J=7.7,1.6Hz,1H)，7.42(dd,J=7.6,1.7Hz,1H).

Example 29

1 ' -butyl-3 ' -chloro-4- [ 2-fluoro-4- (1-hydroxy-1-methyl-ethyl) -phenyl ] -3,4,5, 6-tetrahydro-2H, 1 ' H- [1,4 ' ] bipyridinyl-2 ' -one (E29)

A mixture of intermediate D9 (0.261 g, 0.781 mmol), intermediate D25 (0.223 g, 0.938 mmol) and diisopropylethylamine (0.204 ml, 1.172 mmol) in acetonitrile (11 ml) was heated under microwave irradiation at 180 ℃ for 5 min. The cooled crude mixture was evaporated in vacuo. By column chromatography (silica; DCM/EtOAc/MeOH/NH)₃As eluent) to purify the crude residue. The desired fractions were collected and evaporated in vacuo. The solid residue obtained was treated with diisopropyl ether. The solid was filtered to give compound E29 (0.239 g, 73%). M.p.150.5 ℃.

¹H NMR(400MHz,CDCl₃)ppm0.95(t,J=7.3Hz,3H),1.31-1.43(m,2H)，1.57(s,6H),1.68-1.76(m,2H),1.77(s,1H),1.87-1.96(m,4H),2.86-2.98(m,2H),2.98-3.09(m,1H),3.81(br d,J=12.0Hz，2H),3.93(t,J=7.3Hz,2H),6.03(d,J＝7.5Hz,1H),7.11(d，J=7.5Hz,1H),7.16-7.25(m,3H).

Example 32

1-butyl-3-chloro-4- (1 ' H, 3H-spiro [ 2-benzofuran-1, 4 ' -piperidin ] -1 ' -yl) pyridin-2 (1H) -one (E32)

Intermediate D9 (0.15 g, 0.45 mmol), 3H-spiro [ 2-benzofuran-1, 4' -piperidine in acetonitrile (4 ml)]A mixture of (0.102 g, 0.54 mmol) and diisopropylethylamine (0.097 ml, 0.056 mmol) was heated under microwave radiation at 180 ℃ for 5 minutes. In trueThe cooled crude mixture was evaporated in air. By column chromatography (silica; DCM/EtOAc/MeOH/NH)₃As eluent) to purify the crude residue. The desired fractions were collected and evaporated in vacuo. The solid residue obtained was treated with diisopropyl ether. The solid was filtered to give compound E32 (0.14 g, 84%).

¹H NMR(400MHz，CDCl₃)ppm0.95(t,J＝7.3Hz，3H)，1.30-1.43(m，2H)，1.67-1.79(m，2H)，1.85(dd，J＝13.8，2.20Hz，2H)，2.12(dt，J＝13.0，4.7Hz，2H)，3.25(dt，J＝12.4，2.31Hz，2H)，3.57-3.68(m，2H)，3.94(t，J=7.3Hz，2H)，6.06(d，J＝7.4Hz，1H)，7.12(d，J＝7.4Hz，1H)，7.16-7.34(m，7H).

Example 33

1-butyl-3-chloro-4- (1 ' H-spiro [ 1-benzofuran-3, 4 ' -piperidin ] -1 ' -yl) pyridin-2 (1H) -one (E33)

Intermediate D9 (0.15 g, 0.45 mmol), spiro [ 1-benzofuran-3, 4' -piperidine in acetonitrile (4 ml)]A mixture of (0.102 g, 0.54 mmol) and diisopropylethylamine (0.097 ml, 0.056 mmol) was heated under microwave radiation at 180 ℃ for 5 minutes. The cooled crude mixture was evaporated in vacuo. By column chromatography (silica; DCM/EtOAc/MeOH/NH)₃As eluent) to purify the crude residue. The desired fractions were collected and evaporated in vacuo. The solid residue obtained was treated with diisopropyl ether. The solid was filtered to give compound E33 (0.116 g, 84%).

¹H NMR(500MHz,CDCl₃)ppm0.95(t，J=7.4Hz,3H)，1.30-1.43(m,2H)，1.66-1.79(m，2H),1.86(d,J=13.3Hz,2H),2.05-2.19(m,2H),2.84-2.97(m,2H),3.68(d，J=12.7Hz,2H),3.94(t,J=7.4Hz,2H),4.44(s,2H),6.01(d,J=7.5Hz,1H),6.83(d，J=7.8Hz,1H),6.92(t,J=7.4Hz,1H)，7.07-7.24(m，3H).

Compounds E10, E11, E12, E13, E14, E15, E16, E17, E18, E19, E23, E24, E25 and E26 were prepared according to the reaction procedure described in example 1.

Compound E27 was prepared according to the reaction procedure described in example 9.

Compound E30 and compound E31 were prepared according to the reaction procedure described in example 22.

Physical-chemical data

LCMS-general procedure

HPLC measurements were performed using HP1100 from Agilent Technologies, which included pumps with degasser (quasiset or doublet), autosampler, column oven, Diode Array Detector (DAD), and column specific as in each of the following methods. The flow from the column was split to the MS mass spectrometer. The MS detector was equipped with an electrospray ion source. Nitrogen was used as the atomizer gas. The ion source temperature was maintained at 140 ℃. Data acquisition was performed using MassLynx-Openlynx software.

LCMS method:with the exception of examples E5, E18, E25, E27, E28, E29, E30 and E31, all examples used the following procedure.

In addition to the general procedure: reverse phase HPLC was performed at 60 ℃ on an XDB-C18 cartridge (1.8 μm, 2.1X 30 mm) from Agilent at a flow rate of 1 ml/min. The gradient conditions used were: 90% A (0.5 g/l ammonium acetate solution), 5% B (acetonitrile), 5% C (methanol) to 50% B and 50% C in 6.5 minutes, 7 minutes to 100% B, and equilibrate to initial conditions in 7.5 minutes up to 9.0 minutes. The injection volume was 2. mu.l. High resolution mass spectra (time of flight, TOF) were acquired only in positive ionization mode by scanning from 100 to 750 in 0.5 seconds using a dwell time of 0.1 seconds. The capillary needle voltage was 2.5kV and the cone voltage was 20V. Leucine-Enkephaline is a standard substance used for lock-in mass calibration.

LCMS method: this method was used for examples E5 and E18.

In addition to the general procedure: reverse phase HPLC was performed at 40 ℃ on an ACE-C18 column (3.0 μm, 4.6X 30 mm) from Advanced Chromatography Technologies at a flow rate of 1.5 ml/min. The gradient conditions used were: 80% A (0.5 g/l ammonium acetate solution), 10% B (acetonitrile), 10% C (methanol) to 50% B and 50% C, 7 min to 100% B in 6.5 min, and equilibrated to initial conditions at 7.5 min up to 9.0 min. The injection volume was 5. mu.l. High resolution mass spectra (time of flight, TOF) were acquired only in positive ionization mode by scanning from 100 to 750 in 0.5 seconds using a dwell time of 0.1 seconds. For positive ionization mode, the capillary needle voltage was 2.5kV and the cone voltage was 20V. Leucine-Enkephaline is a standard substance used for lock-in mass calibration.

LCMS method: this method was used in example E25.

In addition to the general procedure: reverse phase HPLC was performed at 60 ℃ on an XDB-C18 cartridge (1.8 μm, 2.1X 30 mm) from Agilent at a flow rate of 0.8 ml/min. The gradient conditions used were: 90% A (0.5 g/l ammonium acetate solution), 10% B (acetonitrile/methanol, 1/1 mixture) to 100% B in 6.0 minutes, held for 6.5 minutes, and equilibrated to initial conditions at 7.0 minutes up to 9.0 minutes. The injection volume was 2. mu.l. Low resolution mass spectra (SQD detector; quadrupole) were acquired only in positive ionization mode by scanning from 100 to 1000 in 0.1 seconds using an interchannel delay of 0.08 seconds. The capillary needle voltage was 3kV and the cone voltage was 20V.

LCMS method: this method was used in example E27.

In addition to the general procedure: reverse phase HPLC was performed at 60 ℃ on a Sunfire-C18 column (2.5 μm, 2.1X 30 mm) from Waters at a flow rate of 1.0 ml/min. The gradient conditions used were: 95% A (0.5 g/l ammonium acetate solution +5% acetonitrile), 2.5% B (acetonitrile), 2.5% C (methanol) to 50% B and 50% C in 6.5 minutes, held for 7 minutes, and equilibrated to initial conditions at 7.3 minutes up to 9.0 minutes. The injection volume was 2. mu.l. High resolution mass spectra (time of flight, TOF) were acquired by scanning from 100 to 750 in 0.5 seconds using a dwell time of 0.3 seconds. The capillary needle voltage was 2.5kV for positive ionization mode and 2.9kV for negative ionization mode. The cone voltage was 20V for both positive and negative ionization modes. Leucine-Enkephaline is a standard substance used for lock-in mass calibration.

LCMS method: this method was used for examples E28, E29, E32 and E33.

In addition to the general procedure: reverse phase HPLC was performed at 60 ℃ on a BEH-C18 column (1.7 μm, 2.1X 50 mm) from Waters at a flow rate of 0.8ml/min without shunting to the MS detector. The gradient conditions used were: 95% A (0.5 g/l ammonium acetate solution +5% acetonitrile), 5% B (acetonitrile/methanol, 1/1 mixture) to 20% A, 80% B in 4.9 minutes, 100% B in 5.3 minutes, held to 5.8 minutes, and equilibrated to initial conditions at 6.0 minutes up to 7.0 minutes. The injection volume was 0.5. mu.l. Low resolution mass spectra were acquired by scanning from 100 to 1000 in 0.1 seconds using an interchannel delay of 0.08 seconds (SQD detector; quadrupole). The capillary needle voltage was 3 kV. The cone voltage was 20V for positive ionization mode and 30V for negative ionization mode.

LCMS method: this method was used for examples E30 and E31.

In addition to the general procedure: reverse phase HPLC was performed at 60 ℃ on an XDB-C18 cartridge (1.8 μm, 2.1X 30 mm) from Agilent at a flow rate of 1 ml/min. The gradient conditions used were: 90% A (0.5 g/l ammonium acetate solution, 5% B (acetonitrile), 5% C (methanol) held for 0.2 min, 3.5 min to 50% B, 50% C, held to 3.65 min, and equilibrated to initial conditions at 3.8 min up to 5.0 min injection volume is 2 μ l high resolution mass spectra (time of flight, TOF) were acquired by scanning from 100 to 750 in 0.5 sec using a 0.3 sec dwell time, capillary needle voltage is 2.5kV for positive ionization mode, and cone voltage is 20V for both positive and negative ionization mode for negative ionization mode 2.9 kV..

Melting Point

For the various compounds, the melting points were determined in open capillaries (open capillary tubes) on a Mettler FP62 apparatus. Melting points were measured with a temperature gradient of 3 ℃ per minute or 10 ℃ per minute. The maximum temperature was 300 ℃. Melting points were read from a digital display and obtained according to experimental error (experimental uncertainty) usually associated with this analytical method.

Nuclear Magnetic Resonance (NMR)

Recording on Bruker DPX400 or Bruker AV-500 spectrometers operating at 400MHz and 500MHz respectively¹H NMR spectrum. All reported chemical shifts () are expressed in ppm relative to tetramethylsilane.

Table 1 lists compounds of formula (I) prepared according to one of the above examples

TABLE 1

Nd: uncertainty

TABLE 2

D. Pharmacological examples

The compounds provided in the present invention are positive allosteric modulators of mGluR 2. These compounds exhibit enhanced glutamate responses by binding to allosteric sites rather than glutamate binding sites. The response of mGluR2 to glutamate concentration is elevated when the compound of formula (I) is present. Due to their ability to enhance receptor function, the compounds of formula (I) are expected to have substantial effects at mGluR 2. The use of the term "described below" is shown in Table 3³⁵S]GTPγS binding assay method the behaviour of positive allosteric modulators tested at mGluR2, this binding assay being suitable for the identification of such compounds, in particular compounds according to formula (I).

[ ³⁵ S]GTP γ S binding assay

[³⁵S]The GTP γ S binding assay is a functional membrane-based assay for studying the function of a G protein-coupled receptor (GPCR), whereby the unhydrolyzed form of GTP, 2, is measured³⁵S]GTP γ S (using gamma-emission)³⁵S-labeled guanosine 5' -triphosphate). The G protein alpha subunit catalyzes the exchange of Guanosine Triphosphate (GTP) to guanosine 5' -diphosphate (GDP), and activation of the GPCR due to agonists, [2 ]³⁵S]GTP γ S becomes integrated and cannot be excised to continue the exchange cycle (Harper (1998) Current Protocols in Pharmacology2.6.1-10, John Wiley&Sons, Inc.). Radioactivity [ alpha ]³⁵S]The amount of GTP γ S incorporation is a direct measure of G protein activity and thus agonist activity can be determined. The mGluR2 receptor appears to be preferentially coupled to the G.alpha.I-protein, a preferred coupling of this approach, and therefore it is widely used to study receptor activation of the mGluR2 receptor in recombinant cell lines and tissues (Schaffhauser et al2003, Pinkerton et al,2004, Mutel et al (1998) Journal of neurochemistry.71:2558-64; Schaffhauser et al (1998) Molecular Pharmacology53: 228-33). Herein, the textIn (1), we describe the use of membranes from cells transfected with the human mGluR2 receptor and engineered by Schaffhauser et al ((2003) Molecular Pharmacology4:798-³⁵S]Use of a GTP γ S binding assay to test the Positive Allosteric Modulation (PAM) performance of the compounds of the invention.

Membrane preparation

CHO cells were cultured to pre-confluence and stimulated with 5mM butyrate for 24 hours before washing in PBS, and then collected by scraping in homogenization buffer (50 mM Tris-HCl buffer, pH7.4, 4 ℃). Cell lysates were homogenized simply (15 s) using an ultra-turrax homogenizer. The homogenate was centrifuged at 23500x g for 10 minutes and the supernatant removed. The pellet was resuspended in 5mM Tris-HCl, pH7.4 and centrifuged again (30000 x g, 20min, 4 ℃). The final pellet was resuspended in 50mM HEPES, pH7.4 and stored in appropriate aliquots at-80 ℃ prior to use. The protein concentration was determined by the Bradford method (Bio-Rad, USA) using bovine serum albumin as a standard.

[³⁵S]GTP γ S binding assay

Measurement of the positive allosteric modulatory activity of mGluR2 of test compounds in membranes containing human mGluR2 was performed using frozen membranes in assay buffer (50 mM HEPES pH7.4, 100mM NaCl, 3mM MgCl)₂50 μ M GDP, 10 μ g/ml saponin) and a minimum predetermined concentration of glutamic acid (PAM assay) or no added glutamic acid in 96-well microplates (15 μ g/assay well, 30 min, 30 ℃) prior to pre-incubation with increasing concentrations of positive allosteric modulator (0.3 nM to 50 μ M) and a minimum predetermined concentration of glutamic acid (PAM assay), the frozen membrane was thawed and briefly homogenized. For PAM determination, EC was used₂₅The concentration of glutamate, i.e.the concentration of glutamate that gives 25% of the maximal response, was pre-incubated and was according to published data (Pin et al (1999) Eur. J. Pharmacol.375: 277-294). In addition³⁵S]After GTP γ S (0.1 nM, f.c.) to reach a total reaction volume of 200 μ l, the microplate was briefly shaken and further incubated to allow the reaction to proceed by activation (30 min, 30 ℃)³⁵S]GTP gamma S3And (6) mixing. Filtration by rapid vacuum on glass fiber filter plates ((Unifilter 96-well GF/B filter plates, Perkin-Elmer, Downers Grove, USA) microplates followed by washing with 300. mu.l of ice-cold wash buffer (Na)₂PO₄.2H₂O10mM，NaH₂PO₄.H₂O10mM, pH = 7.4) three washes, using a 96-well plate cell collector (Filtermate, Perkin-Elmer, USA). The filters were then air dried and 40. mu.l of liquid scintillator (Microscint-O) was added to each well and membrane bound was measured in a 96-well scintillation plate reader (Top-Count, Perkin-Elmer, USA)³⁵S]GTP γ S. The nonspecific value is determined in the presence of cold 10M GTP³⁵S]GTP γ S binding. Each curve was run at 11 concentrations at least once using two samples per data point.

Data analysis

Prism GraphPad software (GraphPad Inc, San Diego, USA) was used to generate ECs that were added₂₅The mGluR2 agonist glutamate for determining Positive Allosteric Modulation (PAM) concentration-response curves of representative compounds of the invention. The curve is fitted to allow the EC to be determined₅₀Four parameter logistic equation of value (Y = Bottom + (Top-Bottom)/(1+10^ ((LogeC)₅₀-X) slope of slope). EC (EC)₅₀Is the concentration of compound that causes half the maximal enhancement of the glutamate response. This is calculated by subtracting the maximal response of glutamate in the presence of a fully saturating concentration of positive allosteric modulator from the response of glutamate without positive allosteric modulator. Then, the concentration that produces half the maximum effect is calculated as EC₅₀。

Table 3.Pharmacological data for the compounds according to the invention

At mGluR2 agonist-predetermined EC₂₅All compounds were tested in the presence of glutamate at concentrations to determine positive allosteric modulation (GTP γ S-PAM). The values shown are 11 concentration response curves from at least one experimentThe average of the two-fold values of (c). All tested compounds showed pEC of greater than 5.0, from 6.05 to 7.20₅₀（-logEC₅₀) The value is obtained. pEC of Individual experiment₅₀The error in the determination of the values is estimated to be about 0.3 log units.

nd = indeterminate

E. Composition examples

As used in all of these examples, "active ingredient" relates to the final compound of formula (I), its pharmaceutically acceptable salts, solvates and stereochemically isomeric forms thereof.

Typical examples of formulations (dosage forms) of the present invention are as follows:

1. tablet formulation

In this example, the active ingredient may be replaced by the same amount of any compound according to the invention, in particular the same amount of any of the exemplified compounds.

2. Suspension liquid

Aqueous suspensions were prepared for oral administration so that 1ml contained 1 to 5mg of one of the active compounds, 50mg of sodium carboxymethylcellulose, 1mg of sodium benzoate, 500mg of sorbitol and 1ml of water ad.

3. Injection preparation

Parenteral compositions are prepared by stirring 1.5% by weight of the active ingredient of the invention in 10% by volume of propylene glycol in water.

4. Ointment

In this example, the active ingredient may be replaced by the same amount of any compound according to the invention, in particular the same amount of any of the exemplified compounds.

Reasonable variations are not to be regarded as a departure from the scope of the invention. It is obvious that the invention thus described may be varied in a number of ways by a person skilled in the art.

Claims (16)

1. Compound

Or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1 and a pharmaceutically acceptable carrier or excipient.

3. Use of a compound according to claim 1 or a pharmaceutical composition according to claim 2 for the manufacture of a medicament for the treatment or prevention of a condition in a mammal, including a human, which treatment or prevention is affected or facilitated by the neuromodulatory effect of mGluR2 positive allosteric modulators.

4. Use of a compound according to claim 1 or a pharmaceutical composition according to claim 2 for the manufacture of a medicament for the treatment or prevention of a central nervous system disorder selected from the group of anxiety disorders, psychotic disorders, personality disorders, substance-related disorders, eating disorders, mood disorders, migraine, epilepsy or convulsive disorders, childhood disorders, cognitive disorders, neurodegeneration, neurotoxicity and ischemia.

5. Use according to claim 4, wherein the central nervous system disorder is an anxiety disorder selected from the group of agoraphobia, Generalized Anxiety Disorder (GAD), Obsessive Compulsive Disorder (OCD), panic disorder, Post Traumatic Stress Disorder (PTSD), social phobia and other phobias.

6. Use according to claim 4, wherein the central nervous system disorder is a psychotic disorder selected from the group of schizophrenia, delusional disorder, schizoaffective disorder, schizophreniform disorder and substance-induced psychotic disorder.

7. Use according to claim 4, wherein the central nervous system disorder is a personality disorder selected from the group of obsessive-compulsive personality disorder and schizoid, schizotypal disorder.

8. Use according to claim 4, wherein the central nervous system disorder is a substance-related disorder selected from the group of alcohol abuse, alcohol dependence, alcohol withdrawal delirium, alcohol-induced psychotic disorder, amphetamine dependence, amphetamine withdrawal, cocaine dependence, cocaine withdrawal, nicotine dependence, nicotine withdrawal, opioid dependence and opioid withdrawal.

9. Use according to claim 4, wherein the central nervous system disorder is an eating disorder selected from the group of anorexia nervosa and bulimia nervosa.

10. Use according to claim 4, wherein the central nervous system disorder is a mood disorder selected from the group of bipolar disorders type I and II, cyclothymic disorder, depression, dysthymic disorder, major depressive disorder and substance-induced mood disorder.

11. Use according to claim 4, wherein the central nervous system disorder is migraine.

12. Use according to claim 4, wherein the central nervous system disorder is epilepsy or a convulsive disorder selected from the group of generalized nonconvulsive epilepsy, generalized convulsive epilepsy, petit mal status epilepticus, grand mal status epilepticus, partial epilepsy with or without impairment of consciousness, infantile spasms, epilepsy partialis continua, and other forms of epilepsy.

13. The use of claim 4, wherein the childhood disorder is attention deficit/hyperactivity disorder.

14. Use according to claim 4, wherein the central nervous system disorder is a cognitive disorder selected from the group of delirium, substance-induced persisting delirium, dementia due to HIV disease, dementia due to Huntington's chorea, dementia due to Parkinson's disease, dementia of the Alzheimer's type, substance-induced persisting dementia and mild cognitive impairment.

15. Use according to claim 4, wherein the central nervous system disorder is selected from the group of anxiety, schizophrenia, migraine, depression and epilepsy.

16. Use of a compound according to claim 1 in combination with an orthosteric agonist of mGluR2, for the manufacture of a medicament for the treatment or prevention of a condition as listed in any one of claims 4 to 15.